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 The voltage-gated potassium ion channel, Kv1.3, in human lymphocytes is a 
promising target for treatment of several autoimmune diseases, including multiple 
sclerosis (MS) and rheumatoid arthritis (RA).  Despite the relevance of this ion channel 
for disease, current techniques to measure Kv1.3 activity are low-throughput, laborious, 
and require significant expertise.  Consequently, studying ion channels in cells of the 
immune system is not accessible to most clinicians and immunologists. 
 This thesis describes the development of a high-throughput assay to measure 
Kv1.3 activity in lymphocytes.  The method is automated, specific for Kv1.3 channels, 
and able to measure Kv1.3 activity in 100-200 lymphocytes within 1 h.  This throughput 
is over 20-fold higher than the throughput of manual patch clamp techniques.   
 Using this high-throughput assay enabled profiling Kv1.3 activity in T cells from 
peripheral blood of patients with MS and RA.  Patients with chronic progressive (CP)
 xv
MS exhibited significantly higher Kv1.3 activity compared to healthy controls or MS 
patients in remission.  Development of metrics to quantify the percentage of T cells with 
“high” Kv1.3 activity made it possible to distinguish between CP-MS patients and 
controls with 100% sensitivity and 94% specificity.  In addition, patients with an active 
form of RA exhibited higher Kv1.3 activity than patients with inactive RA.  These results 
suggest that Kv1.3 activity may be a useful clinical marker for quantifying activity of 
inflammatory autoimmune disorders. 
 Moreover, the assay developed here enabled immunological experiments to study 
the changes in Kv1.3 activity upon T cell stimulation. Kv1.3 activity increased ~3-fold in 
T cells following stimulation. We showed that this upregulation was driven by signaling 
through the interleukin (IL)-2 receptor.  Interestingly, inflammatory cytokines IL-2 and 
IL-15 increased Kv1.3 activity even in the absence of signaling through T cell receptor 
pathways.  These studies suggest that both direct activation of T cells and inflammatory 
cytokines lead to high Kv1.3 activity in vivo.   
 High-throughput electrophysiology introduces a promising new strategy for 
clinical applications such as diagnosis and therapeutic monitoring of autoimmune 
disease.  This work also provides a general methodology that makes the study of ion 
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Potassium Ion Channels in Human T Lymphocytes 
 
 Between 15 and 25 million people in the U.S. suffer from some form of chronic 
autoimmune disorder (1), representing a severe burden both on the quality of life of these 
patients and on the health care system (with an annual cost of ~$120 billion) (2). While 
there are many types of autoimmune diseases, several, including multiple sclerosis (MS), 
rheumatoid arthritis (RA), and type 1 diabetes, arise from abnormal responses of T 
lymphocytes. Physiologically, T lymphocytes play critical roles in specifically 
recognizing foreign pathogens and organizing an effective response (typically involving 
several other cell types) to eliminate these pathogens (3). In many autoimmune disorders, 
however, T cells abnormally recognize self-antigens as foreign and elicit a damaging 
response against the body’s own cells and tissues. In MS, for example, auto-reactive T 
cells can cross the blood-brain-barrier and initiate an inflammatory response against the 
myelin-sheath surrounding axons (4). The resulting damage can cause a range of 
disabling clinical symptoms common in MS, including blurred vision, loss of 
coordination, and feelings of numbness. 
 2
 While significant advances have been made in understanding the pathogenesis of 
many autoimmune diseases, both treatment and effective diagnosis of these disease 
remain significant clinical challenges. Current treatments for MS and RA typically 
include either immunosuppressive drugs or antibodies that neutralize the products of 
inflammatory cells (5, 6). Many of these treatments, however, lead to significant side-
effects or a compromised immune system (7, 8); more importantly, these treatments often 
have limited efficacy (9). In terms of diagnosis, MS especially presents clinical 
difficulties, as current diagnostic schemes often take several years to obtain definitive 
diagnosis (10, 11), well after significant axonal damage has already occurred (12, 13). 
Because of these challenges, it is critical to identify and characterize new therapeutic 
targets and drug candidates that may allow for more effective diagnosis, treatment, and 
monitoring of T cell-mediated autoimmune disease.   
 One such promising target for both diagnosis and treatment of autoimmune 
disease is the voltage-gated Kv1.3 ion channel in the plasma membrane of human T cells 
(14). T cells with high levels of Kv1.3 ion channels have been implicated in the 
pathogenesis of MS, RA, and type 1 diabetes (15, 16). In addition, drug compounds that 
specifically inhibit Kv1.3 ion channel activity ameliorated the symptoms of the 
aforementioned autoimmune diseases in animal models (15, 17).  
 The work presented here explores the use of Kv1.3 ion channel activity as a 
quantitative marker of activity of autoimmune disease. In this introduction, I first discuss 
the different types, roles, and disease-relevance of K+ ion channels in human T cells. 
Then I discuss the challenges traditionally associated with measuring functional activity 
of ion channels. Finally, I outline the goals of this thesis to develop a high-throughput 
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method to study the immunological roles and clinical relevance of Kv1.3 ion channels in 
T cells. 
 
1.1. Types of K+ ion channels in human T cells  
 Ion channels are integral membrane proteins that regulate flux of ionic species, 
such as K+, Na+, and Ca2+, through biological membranes (18). These proteins, which are 
typically specific for a single ionic species, undergo conformational changes (e.g. open 
and close) to regulate the flow of ions through the ion channel, with direction and 
magnitude determined by the electrochemical gradient for the particular ionic species 
(19). The mechanisms controlling the opening and closing of ion channels (i.e. gating) 
include changes in potential across the membrane, binding of intracellular or extracellular 
ligands, or mechanically-derived signals such as stretching (20-22). 
 While the importance of ion flux (especially Ca2+ and K+) to the normal 
functioning of human lymphocytes had been known since the 1970’s (23), the first 
characterization of ion channels in T cells occurred in 1984. The advent of the patch 
clamping technique (24) allowed the identification of a voltage-gated potassium channel 
in the plasma membrane of human T cells (~200-300 channels per cell) by the groups of 
Michael Cahalan and Carol Deutsch (25, 26). Later, genetic studies characterized this 
channel as the Kv1.3 ion channel (also called KCNA3 or type n channels) (27). Key 
biophysical features of the Kv1.3 ion channel included a single channel conductance of 
~12 pS, rapid opening upon depolarization, and slow inactivation upon prolonged 
depolarization (28). Kv1.3 ion channels have been found in other cells of the immune 
system, including B lymphocytes, and macrophages; the channel is also expressed in the 
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following cells: platelets, microglia, osteoclasts, oligodendrocytes, and the olfactory bulb 
(29). 
 Since the identification of Kv1.3 ion channels in T cells, various other Ca2+, Cl-, 
and Na+ channels have been characterized in T cells (30). In terms of K+ channels, the 
group of Michael Cahalan identified a second type of K+ channel in the plasma 
membrane of T cells, a ligand-gated potassium ion channel that is activated by increases 
in intracellular Ca2+ (31, 32). This channel, KCa3.1 (previously called IKCa1), is 
expressed in low numbers (10-20 channels per cell) on resting human T cells and has a 
single channel conductance similar to that of Kv1.3 ion channels. While K+ channels in 
human T cells primarily include only Kv1.3 and KCa3.1, different human lymphocyte 
cell lines and T cells from different mammalian species have very different K+ channel 
profiles compared to human T cells (Table 1.1). These differences can lead to conflicting 
accounts in the literature discussing the roles of individual K+ channels in T cells; they 
also highlight the importance of using human T cells to study K+ channels in the context 
of human autoimmune disease. 
 
1.2. Roles of K+ ion channels in activation of T cells 
 One of the earliest proposed roles of K+ ion channels in T cells was that it 
modulates Ca2+-signaling after stimulation (33). Complex changes in levels of 
intracellular Ca2+ concentrations ([Ca2+]i) are critical for the early stages of T cell 
activation (34-36). Interestingly, different types of Ca2+-signals during activation, such as 
oscillations or sustained elevated [Ca2+]i can lead to different effector functions of T cells 
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(e.g. variations in the types of secreted cytokines), highlighting the importance of factors 
that regulate Ca2+-signaling (37, 38). 
 
Table 1.1.  Types of K+ ion channels in T cells from different species and in selected 






channels (#/cell) Ref. 
CD4+ lymphocytes Kv1.3 (250) KCa3.1 (10) (25, 26, 32) 
CD8+ lymphocytes Kv1.3 (250) KCa3.1 (10) (16) 
B lymphocytes Kv1.3 (100) KCa3.1 (5) (39) 
Human 
Class-switched memory 
B lymphocytes Kv1.3 (2000) KCa3.1 (60) (39) 
Jurkat T cells Human leukemic cell line Kv1.3 (400) SKCa2 (400) (31) 
Louckes cells B cell lymphoma line Kv3.1 (n.k.) not determined (40) 
CD4+ lymphocytes Kv1.3 (20), Kv1.1, Kv1.2, Kv1.6 KCa3.1 (50) (41, 42) 
Mouse 
CD8+ lymphocytes Kv3.1 (20) KCa3.1 (50) (42, 43) 
CD4+ lymphocytes Kv1.3 (20) KCa3.1 (10) (14) 
Rat 
CD8+ lymphocytes Kv1.3 (20) KCa3.1 (10) (14) 
Indicated numbers of specified ion channels in each cell type are approximate numbers in resting 
(non-activated) cells. 




 To discuss the role of K+ channels in regulating Ca2+-signaling, I first need to 
introduce the factors that lead to Ca2+-signaling in T cells upon activation (Fig. 1.1). 
Briefly, activation of T cells begins with specific recognition of antigen (displayed by 
major histocompatibility complex (MHC) heterodimers on the surface of antigen 
presenting cells) by the T cell receptor (TCR) (Fig. 1.1). Engagement of the TCR, as well 
as other co-stimulatory receptors on the T cell (e.g. cluster of differentiation (CD)-28), 
with the antigen presenting cell triggers a rearrangement of the T cell membrane and the 
formation of the immunological synapse (44). The clustering of several protein tyrosine 
kinases and other adaptor proteins leads to the activation of several proteins (e.g. LAT 
and ZAP-70), eventually generating inositol 1,4,5-trisphosphate (IP3), among other 
second messengers (3).  
 Generated IP3 diffuses through the cytosol, eventually binding to IP3-receptors 
(IP3R) on the endoplasmic reticulum (ER). The IP3R is a ligand-gated Ca2+ channel, and 
the binding of IP3 opens this channel to release Ca2+ from the ER into the cytosol (45). 
This initial rise in [Ca2+]i, however, is not sufficient to lead to T cell activation (35). 
Instead, the depletion of the Ca2+-stores in the ER results in the opening of plasma 
membrane Ca2+ release-activated Ca2+ (CRAC) ion channels (46, 47). The opening of 
these channels causes a rapid influx of Ca2+ from the extracellular fluid into the cytosol, 
increasing [Ca2+]i to >300 nM from a resting level of 100 nM . This rise in free calcium 
activates calcineurin, which then activates a number of downstream targets including the 
transcription factor nuclear factor of activated T cells (NF-AT) (48). Activated NF-AT is 
an important transcription factor for expression of several crucial cytokines, such as IL-2, 
IL-4, and tumor necrosis factor, which regulate T cell proliferation, differention, and 
 7
effector responses (3). For an excellent overview of basic immunology and T cell 




Figure 1.1  |  Overview of pathways leading to Ca2+-signaling in T cells. Ion channels play 
several roles in regulating Ca2+-signaling after engagement of the T cell receptor (TCR) with the 
antigen-MHC complex. IP3 (labeled Ins(1,4,5)P3 in the figure) generated by phospholipase C 
(PLC)-γ induces release of Ca2+ into the cytosol from stores in the ER through IP3-gated Ca2+ ion 
channels. This release opens CRAC channels in the plasma membrane to facilitate influx of Ca2+ 
into the cell. Kv1.3 and KCa3.1 (labeled IKCa1) channels facilitate this influx by maintaining a 
negative membrane potential (30). Efflux of K+ through these channels counterbalances increased 
cytosolic Ca2+ levels, and allows for sustained Ca2+-signaling. Figure from (49). 
 
  
  K+ ion channels indirectly regulate the activation of NF-AT by allowing for a 
sustained increase in [Ca2+]i after stimulation. The magnitude of the Ca2+ influx is 
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determined solely by the electrochemical gradient of Ca2+, meaning that maximal Ca2+-
influx after stimulation requires a negative potential across the plasma membrane (35). 
K+ channels allow for this negative membrane potential in T cells (30). Kv1.3 ion 
channels set the resting membrane potential of T cells (-50 to -60 mV) to allow 
immediate Ca2+-influx upon opening of CRAC channels (30, 50). During stimulation, 
both Kv1.3 and KCa3.1 channels contribute to maintaining a negative membrane 
potential upon increased [Ca2+]i to allow sustained Ca2+-influx (30). Activation of 
KCa3.1 channels (by binding of Ca2+ to calmodulin sensors on the cytoplasmic side of 
the channel) or activation of Kv1.3 channels (by membrane depolarization from elevated 
[Ca2+]i) leads to efflux of K+ from the cell in order to maintain a negative membrane 
potential (45). 
 Drug compounds that block Kv1.3 and KCa3.1 (Table 1.2) alter Ca2+-signaling in 
T cells (31). Compounds that block Kv1.3 ion channels depolarize the plasma membrane 
of T cells (by ~+20 mV) and correspondingly reduce the influx of Ca2+ after stimulation 
(51-53). Drugs that block KCa3.1 channels also reduce Ca2+ influx after stimulation, 
although this effect is most pronounced in pre-activated T cells (54). Importantly, these 
drugs (especially compounds that block Kv1.3 activity) have immunosuppressive effects 
by affecting processes associated with Ca2+-signaling, including expression of IL-2 
mRNA and proliferation of T cells (55-57). As a consequence, development of drugs that 
block K+ ion channels is of great interest to pharmaceutical companies and several 
academic research groups (Table 1.2). Interestingly, drug compounds that block both 
Kv1.3 and KCa3.1 have a greater effect on reducing Ca2+-influx and suppressing 
proliferation of T cells from peripheral blood than block of either channel alone (17, 52). 
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Such studies highlight the importance of the interplay between Kv1.3 and KCa3.1 ion 
channels in regulating Ca2+ flux and T cell activation. 
 
Table 1.2.  Sensitivity and specificity of selected drug compounds that block K+ 
channels in human T cells 
Drug compound Kv1.3 (IC50) 
KCa3.1 
(IC50) 
Other channels affected (IC50) 
ShK  11 pM 30 nM Kv1.1 (25 pM), Kv1.6 (200 pM), Kv3.2 (2.5 nM) 
ShK-F6CA  48 pM not determined Kv1.1 (4 nM) 
ShK-Dap22 52 pM > 1 μM Kv1.1 (1.8 nM), Kv1.2 (39 nM), Kv1.5 (> 1 μM), Kv1.6 (10 nM)  
Margatoxin 110 pM no effect Kv1.1 (10 nM), Kv1.2 (500 pM)  
Noxiustoxin 1 nM no effect Kv1.2 (2 nM) 
Charybdotoxin 3 nM 5 nM Kv1.2 (14 nM), Kv1.5 (>100 nM),  KCa1.1 (3 nM) 
Psora-4 3 nM > 5 μM Kv1.1 (62 nM), Kv1.2 (49 nM), Kv1.4 (202 nM), Kv1.5 (8 nM), Kv1.7 (100 nM) 
TRAM-34 3 μM 20 nM  
Nifedipine 5 μM 4 μM L-type Ca2+ channels, Kv1.5 
Verapamil 6 μM 28 μM hERG (143 nM), L-type Ca2+ channels 
TEA 10 mM 24 mM General blocker of K+ channels 
Abbrevations: ShK, peptide from Stichodactyla helianthus toxin; ShK peptide with an 
attached fluorescein-6-carboxylic acid; ShK-Dap22, ShK peptide with an attached positively 
charged, non-natural amino acid diaminopropionic acid; TEA, tetraethylammonium chloride  
Table adapted from references (29, 49) 
 
1.3. Roles of Kv1.3 ion channels in volume regulation of T cells 
 In addition to maintaining a negative membrane potential, Kv1.3 ion channels 
also play important roles in regulating the volume of T cells (30). When lymphocytes are 
placed in a hypotonic solution, they initially swell due to rapid influx of H2O; however, 
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this swelling rapidly reverses, and T cells return to normal cell volume in the hypotonic 
solution (30, 58). This ability of T cells to regulate their volume in a range of solutions 
with different osmolarities is known as regulatory volume decrease (RVD), and it is 
mediated by plasma membrane ion channels (30). The initial swelling of the T cell opens 
swelling-activated Cl- channels, leading to efflux of Cl- and a corresponding 
depolarization of the plasma membrane (22). This depolarization activates voltage-
sensitive Kv1.3 channels, which help to reduce the volume of T cells through two 
mechanisms: (i) the opening of Kv1.3 channels maintains a negative membrane potential 
to permit continued Cl- efflux; and (ii) efflux of K+ ions combined with efflux of Cl- ions 
reduces intracellular osmolarity (towards matching the hypotonic solution) at a normal T 
cell volume (30, 58). Correspondingly, blocking Kv1.3 ion channels inhibits RVD (58). 
This ability of T cells to regulate volume is important given variations in osmolarity of 
microvasculature and during extravasation into tissues (30, 59). Kv1.3 ion channels, 
therefore, may play a critical role in mediating the migration of T cells after activation 
through regulation of volume. 
 
1.4. Phenotype-specific regulation of K+ ion channels upon activation 
 After stimulation, human T cells upregulate expression of mRNA and increase 
translation of many proteins that are critical for effector functions, differentiation, and 
proliferation (3). K+ ion channels are among these proteins with increased levels after 
activation. KCa3.1 channels upregulate from ~10 to over ~300 channels per cell through 
increased expression of mRNA promoted by signaling through protein kinase C (PKC) 
pathways (54). Activity of Kv1.3 ion channels also increases after stimulation by a factor 
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of three (60, 61), although Kv1.3 mRNA expression does not change after stimulation 
(62, 63) and the pathways leading to this functional increase in activity are not known. 
 Interestingly, the changes in ion channel activity that T cells undergo after 
stimulation depend on the particular phenotype of T cell (16). There are many different 
“types” of T cells, which can be differentiated on the basis of their cell surface markers 
and secreted cytokines (3). Three cell-surface markers that have been used to classify T 
cells into “memory” and “naïve” subsets are the C-C chemokine-receptor 7 (CCR7, 
which hones T cells to lymph nodes), CD45RA (an isoform of a tyrosine phosphatase), 
and CD62L (L-selectin, a cell adhesion molecule that enables migration to lymphoid 
tissues). The corresponding phenotypes are the following: naïve T cells (Tnaive, CCR7+, 
CD45RA+, CD62L+) which have not previously experienced antigenic stimulation; 
central memory T cells (Tcm, CCR7+, CD45RA-, CD62L+), which persist from a previous 
antigenic response and hone to the lymph nodes for rapid re-activation; effector memory 
T cells (Tem, CCR7-, CD45RA-, CD62L-), which also persist from a previous antigenic 
stimulation and infiltrate peripheral tissues to exert immediate effector functions after 
stimulation; and in CD8+ subset of T cells, CD45RA+ effector memory T cells (Temra, 
CCR7-, CD45RA+, CD62L-) (Fig. 1.2) (64-66).  
 In a seminal work, Wulff et al. found that in vitro-activated Tem cells expressed 
significantly higher levels of Kv1.3 ion channels (~5-fold) than activated Tnaive or Tcm 
(16). Conversely, Tnaive and Tcm expressed significantly higher levels of KCa3.1 channels 
than Tem (Fig. 1.2) (16). The physiological roles of the selective increase in K+ channels 
after activation of T cells are not known but may be related to Ca2+-signaling specific to 
particular phenotypes (16, 37). Interestingly, proliferation of Tem cells (isolated from the 
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synovial fluid of patients with RA) was suppressed by a 60-fold lower concentration of a 
specific inhibitor of Kv1.3 ion channels compared to the concentration that blocked 
proliferation of Tnaive and Tcm cells (42, 67). Drug compounds that block Kv1.3 ion 
channels, therefore, may offer a selective means for inhibiting activation of Tem cells 
while allowing proliferative and effector responses of naïve cells (42). 
 
 
Figure 1.2  |  Kv1.3 and KCa3.1 activity in effector and memory subsets of human T cells 
isolated from peripheral blood. (A) Example of flow cytometric analysis of effector and 
memory subsets of CD4+ (left) and CD8+ T cells isolated from peripheral blood of a healthy 
control subject. Naïve, central memory (Tcm), effector memory (Tem), and CD45RA+ effector 
memory (Temra) subsets were identified according to surface expression of CCR7 and CD45RA. 
(B) Representation of Kv1.3 and KCa3.1 (identified as IKCa1 above) ion channels in resting and 
activated human T cells of the various effector and memory subsets. Note that resting subsets 
have very similar numbers of Kv1.3 ion channels, but that Tem cells upregulate Kv1.3 ion 




1.5. Links between Kv1.3 ion channels and autoimmune disease  
 The ability to selectively suppress Tem cells with compounds that block Kv1.3 
activity offers a promising approach for treating autoimmune disease because Tem cells 
are implicated in the pathogenesis of several autoimmune disorders. In patients with MS, 
autoreactive, myelin-specific T cells are of the Tem phenotype (68, 69). Also, T cells 
isolated from inflammatory infiltrates from the brains of post-mortem MS patients 
exhibited characteristics of Tem cells (70). In patients with RA, T cells isolated from the 
synovial fluid of inflamed joints were predominantly Tem cells (71). In addition to MS 
and RA, type 1 diabetes, psoriasis, and uveitis are also among the autoimmune diseases 
in which Tem cells play central roles in initiating a damaging inflammatory response 
against self-tissues or cells (Table 1.3) (14). The characteristic that Tem cells persist from 
inflammatory responses provides a pathological basis for the chronic nature of these 
autoimmune disorders.  
 Extensive animal experiments demonstrated the ability of drug compounds that 
block Kv1.3 activity (and suppress Tem cells) to treat autoimmune disease.  The first 
report of using drug compounds that block Kv1.3 ion channels for treatment of an animal 
model of disease appeared in 1997 from Koo et al., who used margatoxin to prevent 
delayed type hypersensitivity and mixed lymphocyte reaction in miniswine (72). In 2001, 
Beeton et al. used the selective blocker of Kv1.3 ion channels, ShK, to prevent the onset 
of experimental autoimmune encephalomyelitis (EAE), an animal model of MS, in rats 
(17). Interestingly, this drug compound also improved the course of EAE when 
administered after onset of disease (17). Later studies showed that treatment with ShK 
also improved symptoms in animal models of RA, type-1 diabetes, and allergic contact 
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dermatitis (15, 73). These studies highlighted the promise of drug compounds that block 
Kv1.3 activity as a general approach for treatment of Tem-mediated autoimmune disease; 
developing compounds that are suitable for use in humans and specifically block Kv1.3 
activity is a focus of several research groups and pharmaceutical companies (49, 74). 
 
Table 1.3.  Autoimmune diseases in which effector memory T cells are implicated in 
the pathogenesis 
Disease Target organ Symptoms 
Multiple sclerosis Central nervous system 
vision loss, tremor, speech difficulty, 
memory loss, loss of coordination 
Rheumatoid arthritis Joints joint pain and swelling, morning stiffness, gradual erosion of joints 
Psoriasis Skin dry, scaly skin and inflammation 
Type 1 diabetes mellitus Pancreas hyperglycemia 
Uveitis Eyes inflammation of middle layer of eye, blurred vision occasionally progressing to blindness 
Chronic graft versus host 
disease Various 
bone marrow transplant complication, T 
cells from graft attack host resulting in liver, 
skin, and gastrointestinal damage 
Hashimoto disease Thyroid 
hypothyroidism, slowed metabolism, 
impaired memory, slowed speech, sensitivity 
to cold 
Table adapted with modifications from reference (14) 
  
 In addition to being a promising target for treating Tem-mediated autoimmune 
diseases, Kv1.3 ion channels may also serve as a marker for disease. As mentioned 
previously, Tem cells exhibit high levels of Kv1.3 activity upon activation, thus making 
Kv1.3 activity a potential marker to identify activated, and possibly pathogenic, Tem cells 
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(14). Studies from the Chandy group at the University of California, Irvine confirmed 
that the autoreactive disease-specific T cells from patients with MS, RA, and type 1 
diabetes exhibited high levels of Kv1.3 activity upon activation (Fig. 1.3) (15, 16). T cells 
from healthy controls specific for antigens involved in MS-, RA-, or type 1 diabetes-
antigens did not have high levels of Kv1.3 ion channels when activated, as these cells 
were predominantly Tnaive or Tcm (15, 16). In addition, T cells with high Kv1.3 activity 
were found in the lesions in the brain of post-mortem MS patients (70). These studies 
suggest that identifying T cells with high Kv1.3 activity (e.g. from peripheral blood or 




Figure 1.3  |  High numbers of Kv1.3 ion channels in auto-reactive, disease-specific T cells 
from patients with MS and RA. (A) Number of Kv1.3 ion channels per cell in activated myelin-
reactive T cell lines derived from the peripheral blood of MS patients (left) and control subjects 
(right). Each point represents the average ± standard error of Kv1.3 measurements in 20-30 cells 
from an MS patient or control subject using manual patch clamp. Cells were activated with 50 ng 
mL-1 soluble anti-CD3 antibodies. Figure from Wulff et al. (16). (B) Number of Kv1.3 ion 
channels per cell in T cells isolated from the synovial fluid of patients with RA and osteoarthritis 
(OA), or in T cells from peripheral blood from RA patients. Points represent the average ± 
standard error of an average of 10-15 cells from an individual RA or OA patient. T cells were 
activated with anti-CD3 antibodies for 48 h prior to electrophysiology experiments. Figure from 
Beeton et al. (15). Note that the y-axis for panel (B) aligns with the y-axis of panel (A) to afford 
comparison of Kv1.3 activity between activated MS T cell lines and activated T cells from 
synovial fluid.  
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1.6. Techniques to study ion channel activity in T cells 
 Previous studies of Kv1.3 ion channels in T cells have employed manual patch 
clamping to measure functional activity (25, 26). This technique was developed by Neher 
and Sakmann in the 1970’s (Nobel Prize award in 1991) and allows the extremely 
sensitive measurement of ion channel activity in a wide range of cell types (24). Briefly, 
the technique involves contacting an individual cell with a glass pipette and forming a 
tight electrical seal between the pipette and the cell (Fig. 1.4). Typically, a “patch” of 
membrane from the attached cell is removed by suction or a voltage pulse, affording 
access to the intracellular solution of the cell. Sensitive electronics then detect the flow of 
ions through ion channels in the plasma membrane of the attached cell (whole-cell patch 
clamping) after application of a stimulus, usually either a change in voltage across the 
membrane or addition of a ligand (24). While patch clamping is a versatile technique 
capable of measuring even single-channel electrical currents, it is also serial, low-
throughput, and requires significant expertise (75). A highly-trained operator can 
typically record whole-cell currents in 20-30 cells per day.   
 In addition to limitations of manual patch clamping for measuring functional 
activity of Kv1.3 ion channels in T cells, fluorescence-based approaches to quantifying 
surface expression of Kv1.3 channels also pose difficulties. The number of Kv1.3 ion 
channels in human T cells (100-300 channels) is close to the lower limit afforded by flow 
cytometry due to auto-fluorescence (76). Also, there is currently no commercially 
available monoclonal antibody to Kv1.3 ion channels. Beeton et al. developed a 
fluorescent analogue of a blocker of Kv1.3 ion channels (ShK-6FAM) that has a high 
affinity for Kv1.3 channels (77). This molecule, however, displays several positive 
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charges at neutral pH (74), which can lead to non-specific adsorption on negatively-
charged surfaces including all membranes. The combination of non-specific adsorption 
and low levels of fluorescence leads to significant problems in using ShK-6FAM to 
evaluate expression of Kv1.3 ion channels in T cells (personal communication with Dr. 
Christine Beeton, 2007). The low-throughput and difficulties associated with patch clamp 
combined with the lack of a fluorescent assays to quantify Kv1.3 expression has the 
consequence that the study of ion channels in cells of the immune system is not 
accessible to most clinicians and immunologists. 
  
1.7. Development of technology for performing high-throughput 
electrophysiology 
 The low throughput of manual patch clamping is primarily associated with the 
process of using a micromanipulator to attach a glass pipette to individual cells. In the 
past 10 years, however, advances in micro-fabrication and micro-machining technologies 
have led to techniques for recording ion channel activity without the use of “patch” 
pipettes (78, 79). These automated technologies employ planar substrates containing a 
microfabricated or machined pore (< 2 μm), in which a single cell is positioned over the 
micropore, typically through the application of suction (Fig. 1.4) (80). The establishing of 
a tight electrical seal between the cell and the planar substrate then allows for recordings 
of ion channel activity through ion channels of the attached cell (79). Notably, Schmidt, 
Mayer, and Vogel performed the first recording of ion channel activity on a planar 
substrate using giant liposomes as models of cells (81); the first example of ion channel 
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Figure 1.4  |  Comparison of traditional patch clamp to recently-developed planar patch 
clamp techniques.  (A) Example of manual (traditional) patch clamp of a T cell.  Under a 
microscope, a single T cell is selected and attached to a glass pipette with the aid of a 
micromanipulator. The serial process of selecting T cells and achieving stable seals limits the 
throughput of this technique. Panel from (16). (B) Planar patch clamp technology, in which cells 
are added to a planar substrate containing a micropore (inset depicts the micropore region). One 
single cell attaches to the micropore, affording a stable electrical seal for patch clamp 
experiments. Because there are no moving pipettes or manual techniques involved with planar 
patch clamp, the process can be automated and carried out in a parallel format. Panel from (83). 
 
 
     
 Based on the concept of planar patch clamp, several commercial technologies 
have emerged that allow automated and parallel recordings of ion channel activity in cells  
(75, 83-86). These medium- to high-throughput electrophysiology devices vary in 
throughput (from 16 - 384 cells per experiment) and types of planar substrates 
(polyimide, glass, and silicon-nitride) (see Table 1.4 for a comparison of different 
technologies). Typically, these devices have been used for high-throughput screening of 
drug compounds, either to select for drugs that target certain ion channels or to ensure 
that other drugs do not inadvertently affect ion channel activity (86). Importantly, these 
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studies employed cell lines with a single recombinantly expressed ion channel type (85, 
86); there have been no reports of using high-throughput patch clamp technology to 
examine ion channel activity in a primary cell type such as T cells.  
 
Table 1.4.  Comparisons of commercially available platforms for performing 




(MΩ)* Format Comments 
IonWorks HT 
(MDS) ~100 
384 well substrate, one 
micropore per well, 48-
parallel electrodes, perforated 
patch 
Highest throughput, automated 
compound addition, low seals, no 
intracellular perfusion  
IonWorks 
Quattro (MDS) 30-50 
384 well substrate, 64 
micropores per well, 
perforated patch 
High percentage of success for 
each well, does not provide 
distributions of current from 
single cells 
Patchliner 
(Nanion) > 1000 
2, 4, or 8 wells in parallel, 
one micropore per well 
Intracellular and extracellular 




16-48 wells in parallel, one 
micropore per well 
Multiple compound additions, 




16 wells in parallel, one 
micropore per well 
Multiple compound additions, no 
intracellular perfusion 
* “Seals” refers to the typical seal resistance between cells and the micropore of the planar 
substrate of the specified technology. 
Table adapted from reference (86) 
 
1.8. Overview of thesis 
 In this thesis, we use high-throughput electrophysiology technology to develop an 
automated assay for measuring Kv1.3 activity in human T cells. In Chapter 2, we present 
the details and validations of this method. In Chapter 3, we apply the high-throughput 
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assay to study the immunological pathways that regulate Kv1.3 activity in T cells. In 
Chapter 4, we profile Kv1.3 activity in T cells from patients with MS and RA to study the 
relationship between disease activity and Kv1.3 activity in T cells from peripheral blood. 
In Chapter 5, we evaluate the potential and feasibility of the high-throughput assay for 
measuring Kv1.3 activity for clinical and immunological studies and discuss potential 
future applications. This work provides an enabling and general technique to measure 
voltage-gated ion channels in a range of primary cell types, and it provides a new tool 
that may be useful for diagnosis and therapeutic monitoring of human autoimmune 
disease.  
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High-Throughput Profiling of Ion Channel Activity in Primary Human 
Lymphocytes 
 
 We present a high-throughput method to quantify the functional activity of 
potassium (K+) ion channels in primary human lymphocytes. This method is rapid, 
automated, specific (here for the voltage-gated Kv1.3 ion channel), and capable of 
measuring, in parallel, the electrical currents of over 200 individual lymphocytes isolated 
from freshly drawn blood. The statistics afforded by high-throughput measurements 
allowed direct comparison of Kv1.3 activity in different subsets of lymphocytes, 
including CD4+ and CD8+ T cells, γδ T cells, and B cells. High-throughput measurements 
made it possible to quantify the heterogeneous, functional response of Kv1.3 ion channel 
activity upon stimulation of CD4+ and CD8+ T cells with mitogen. These experiments 
enabled elucidation of time-courses of functional Kv1.3 activity upon stimulation as well 
as studies of the effects of the concentration of mitogenic antibodies on Kv1.3 levels. The 
results presented here suggest that Kv1.3 ion channel activity can be used as a functional 
activation marker in T cells, and that it correlates to cell size and levels of a surface 
antigen, CD25. Moreover, this work presents an enabling methodology that can be 
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applied widely, allowing high-throughput screening of specific voltage-gated ion 
channels in a variety of primary cells. 
 
2.1. Introduction 
 Ion channels in cells of the immune system serve important roles in generating an 
effective response to pathogens (1). The plasma membranes of lymphocytes contain a 
variety of calcium (Ca2+), potassium (K+), and chloride (Cl-) ion channels that help to 
regulate at least four cellular properties, including: (i) the membrane potential; (ii) signal 
transduction, especially in the activation of different cell types; (iii) cell volume; and (iv) 
cell motility (2).  
 One of the best studied ion channels in immune cells is the voltage-gated K+ ion 
channel, Kv1.3, in human T cells (3, 4). Kv1.3 ion channels regulate the resting potential 
of T cells and help to regulate Ca2+-signaling after activation of T cells (5, 6). This Ca2+-
signaling leads to the expression of cytokines that mediate proliferation and 
differentiation of effector T cells as well as regulation of the inflammatory response (7). 
Interestingly, T cells with high Kv1.3 ion channel activity have been implicated in the 
pathogenesis of human autoimmune diseases including multiple sclerosis, type I diabetes, 
and rheumatoid arthritis (8-10). Therapeutic compounds that specifically block Kv1.3 
activity have led to amelioration of the symptoms of the above diseases in animal models 
(9, 11). The Kv1.3 ion channel is, therefore, a promising therapeutic target for 
autoimmune diseases (12-15), and studying the roles and functions of Kv1.3 channels in 
primary human T cells, as well as other cells of the immune system, is critical for 
understanding the consequences of therapies that involve blocking Kv1.3 channels. 
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 A significant challenge in studying Kv1.3 ion channels in primary lymphocytes is 
the lack of an accessible and high-throughput technique to conduct parallel recordings of 
functional ion channel activity in various subpopulations of cells. Previous studies have 
employed manual patch-clamping (8, 16), which involves contacting a single cell with a 
glass micropipette to gain electrical access to the inside of the cell followed by measuring 
the flow of ions through the plasma membrane of the entire cell (17). While this manual 
whole-cell patch clamping technique is extremely sensitive and versatile, the technique is 
serial, has low throughput, and requires significant expertise (18). As a result, quantifying 
ion channel activity in primary cells of the immune system under various conditions has 
thus far not been a feasible approach for most immunologists and clinicians.  
 Here, we present an automated, high-throughput method capable of measuring 
functional Kv1.3 ion channel activity in over 200 individual lymphocytes within one 
hour. In recent years, several new technologies have emerged that automate the patch-
clamp method, using different strategies (19-22) and offering varying degrees of 
throughput (typically 16 – 384 cells per run). In the present study, we used a high-
throughput patch clamp device capable of measuring up to 384 cells per experiment (23, 
24) to implement an automated assay that is: (i) capable of measuring voltage-gated ion 
channels in a primary cell type, specifically different subsets of lymphocytes; (ii) specific 
for endogenous, wild-type levels of Kv1.3 ion channels from human subjects; and (iii) 
able to compare different T cell populations in parallel. We applied this assay to elucidate 
time-courses of Kv1.3 activity after T cell stimulation as well as the effects of different 
stimulation conditions on the regulation of the activity of this ion channel. This study 
presents the first example of functional high-throughput screening of ion channels in a 
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primary cell type and makes it possible to place the upregulation of Kv1.3 activity into 
the context of the signaling cascade during activation of human T cells.  
 
2.2. Experimental Section 
 Human subjects. We obtained peripheral venous blood from 12 healthy subjects 
without history of autoimmune disease. We obtained multiple blood samples from six 
subjects. The Institutional Review Board at the University of Michigan approved blood 
draws and protocols. 
 High-throughput electrophysiology assay. We used an IonWorks HT high-
throughput electrophysiology instrument (MDS Analytical Technologies, Sunnyvale, 
CA) made available via collaboration with the original developers of the technology 
(Essen Instruments, Ann Arbor, MI) to measure Kv1.3 currents in lymphocytes. 
Separated lymphocytes were suspended in Dulbecco’s phosphate buffered saline (D-PBS, 
with Ca2+ and Mg2+) at a concentration of 5×105 cells mL-1 and stored at room 
temperature for 30 min prior to electrophysiology experiments. A typical experiment 
required 2.2 mL of cell suspension. Integrated fluidics within the IonWorks instrument 
then automatically dispensed cells into the single-use 384-well “patch plate”. The bottom 
of these plates consisted of microfabricated polyimide that contained one micropore in 
each well. For experiments with lymphocytes, we typically used only patch plates with an 
open hole resistance (i.e. before adding cells) of at least 3.0 MΩ (corresponding to hole 
diameters below 1.8 µm, measured in D-PBS with Ca2+ and Mg2+). In each experiment, 
CD4+ T cells occupied half of the patch-plate (192 microwells), and the other half was 
occupied by either CD8+ T cells, B cells, or γδ T cells, allowing for direct comparisons 
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between subsets of lymphocytes. The IonWorks HT instrument applied and maintained 
suction from below each well to seal a single lymphocyte over the hole in each well of 
the patch plate. The intracellular recording solution consisted of 100 mM K+ D-gluconic 
acid, 50 mM KCl, 3 mM MgCl2, 5 mM EGTA pH 7.3 (all from Sigma-Aldrich). To gain 
electrical access to the interior of the sealed cells, automated fluidics introduced a pore-
forming peptide (amphotericin B, 100 µg mL-1 with 0.2% DMSO) in the intracellular 
recording solution. Recordings started 5 min after introduction of the peptide. 
 To record Kv1.3 ion channel currents, T cells were first voltage-clamped at a 
holding potential of -80 mV for 30 s before applying a depolarizing step pulse from -80 
mV to +40 mV for 300 ms. This voltage-step opened voltage-gated channels, and the 
resulting current was recorded in parallel using an array of 48 Ag/AgCl electrodes. After 
performing this process in all of the 384 wells, the integrated fluidics array added a 
specific blocker of Kv1.3 channels, 6-FAM-AEEAc-Stichodactyla helianthus neurotoxin 
peptide (ShK-F6CA, Bachem Biosciences, King of Prussia, PA), to a final concentration 
of 72 nM to each well of the patch plate (25). After an incubation time of 3 min to 
specifically block all Kv1.3 ion channels, electrical currents from the attached cells were 
then measured again using the same voltage protocols as described above. We defined 
Kv1.3 current as the difference between the pre- and post-compound currents (see Figure 
2-App.3 for detailed information on data processing algorithms as well as Supporting 
Methods in section 2-App.Methods for details on wash protocols, cell separations and 
culture, flow cytometry assays, and statistical analyses). 
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2.3. Automated high-throughput profiling of Kv1.3 ion channels in human 
lymphocytes 
 To establish a method that enables rapid profiling of Kv1.3 ion channel activity in 
different subtypes of lymphocytes from human blood, we adopted a high-throughput 
patch-clamp technology that had previously been developed for drug-screening in the 
pharmaceutical industry (Fig. 2.1) (23, 24). This technology is based on 384 microwells 
with a single micropore at the bottom of each well (Fig. 2.1A). Cells in suspension are 
automatically positioned onto these micropores by suction, enabling up to 384 whole-cell 
patch clamp recordings within one hour. An integrated microfluidics array dispenses 
cells, drugs, or other molecules in solution to each of the 384 wells, while keeping the 
cells attached to the micropore. Previous applications of this high-throughput 
electrophysiology technology employed cell lines (diameter typically > 15 µm) that over-
expressed one particular, recombinant ion channel protein (26). To the best of our 
knowledge, there have been no published manuscripts of high-throughput measurements 
of ion channels in primary cells, possibly because of difficulties in isolating primary cell 
types in large numbers and possibly because the number of a particular endogenous ion 
channel in wild-type primary cells may have been considered too low to detect. We chose 
lymphocytes as examples of primary cell types because: (i) the molecular mechanisms of 
activation of these cell is fundamentally important for an effective immune response; (ii) 
these cells can be obtained in high yield from peripheral blood; (iii) they can be easily 
activated ex vivo; and (iv) emerging evidence identifies ion channels in lymphocytes as 
potential drug targets for treatment of autoimmune disease. These cells, however, offer 
several challenges to high-throughput screens because of their small sizes (~8 µm 
 38
diameter for T cells from blood (27)) and diversity with respect to endogenous ion 
channels in their plasma membranes (2).  
 To adapt high-throughput patch clamp technology for a specific ion channel (here 
the voltage-gated potassium channel Kv1.3) in subsets of lymphocytes without over-
expressing the channel protein, implemented the following four strategies. First, we 
isolated specific lymphocyte subsets (CD4+ T cells, CD8+ T cells, γδ T cells, and B cells) 
using commercially-available magnetic beads coated with an antibody against particular 
surface markers (e.g. CD4) which are expressed on the blood cell subset of interest. 
Second, we specifically selected 384-well “patch-plates” with micropore sizes below 1.8 
µm (Fig. 2.1A). Third, we developed a differential measurement of electrical current 
through individual cells before and after application of a highly specific blocker of Kv1.3 
ion channels (the ShK-F6CA peptide) (25, 28). This strategy ensured specificity for the 
Kv1.3 ion channel while subtracting possible “leak” currents (Fig. 2.1B,C). We 
confirmed specificity, as well as efficacy of block, by testing additional compounds that 
either block Kv1.3 ion channels (margatoxin and Psora-4) (12) or have minimal effect 
(TRAM-34) (12) on these channels (Figs. 2-App.1, 2-App.2). And fourth, we used data 
processing algorithms (i) to exclude cells that did not remain attached to the micropore 
throughout the experiment and (ii) to compute the magnitude of Kv1.3-specific currents 
after the differential measurements (Fig. 2-App.3). 
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Figure 2.1  |  High-throughput method for measuring Kv1.3 ion channel activity in 
lymphocytes. (A) Isolated lymphocytes in suspension (5 × 105 mL-1) were dispensed into a 384-
well patch plate (~2,500 cells per well). The bottom of each well contained a micropore with a 
diameter of 1.6 – 1.8 µm. Suction resulted in positioning of a single lymphocyte over the hole in 
each well to form a stable electrical seal (>75 MΩ) with the “patch plate”. (B) After electrical 
access to the cytoplasm was obtained, a depolarizing voltage step function from -80 mV to +40 
mV was applied across the cell membrane. This depolarization opened voltage-gated ion 
channels, and the resulting whole-cell current through the plasma membrane was recorded. (C) 
While the same cell was still attached, a specific blocker of Kv1.3 channels was added to each 
microwell. A second depolarizing step was applied to the cell, and the resulting whole-cell 
current was recorded. The Kv1.3-specific current was defined as the difference between the pre-
blocker (B) and post-blocker (C) electrical currents. 
  
 
 This high-throughput assay enabled us to profile Kv1.3 activity rapidly in four 
different subsets of lymphocytes isolated directly from fresh blood (Fig. 2.2). In each 
experiment, we measured two subsets on the same patch plate (all cells were seeded at 
the same concentrations), with CD4+ T cells on one half (192 wells) and either CD8+ T 
cells, γδ T cells, or B cells on the other half (see 2-App.Table for comparisons and 
discussions of throughput, which can depend on lymphocyte subtype). Examining Kv1.3 
currents, we found that although the mean Kv1.3 currents of each of the four lymphocyte 
subtypes were similar, histograms representing the distribution of Kv1.3 currents through 
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78 – 1220 individual cells showed significant differences between subtypes (Fig. 2.2). 
CD4+ and CD8+ T cells displayed similar distributions of Kv1.3 currents; for both of 
these T cell types, more than 98% of whole-cell currents had a magnitude between 0 and 
0.5 nA (Fig. 2.2A,B). In contrast, the majority of B cells displayed Kv1.3 currents below 
0.2 nA; however ~5% of B cells exhibited very high Kv1.3 activity (currents > 1.25 nA) 
(Fig. 2.2C). These rare, large currents in B cells were the largest Kv1.3 currents that we 
observed from all subsets of primary cells isolated from freshly drawn blood. These cells 
presumably represented activated class-switched IgD- CD27+ B cells that express large 
numbers of Kv1.3 channels.(29) γδ T cells, which previously had not been characterized 
with respect to Kv1.3 ion channel activity, displayed distributions of Kv1.3 currents more 
similar to B cells than CD4+ or CD8+ T cells (Fig. 2.2D). The majority of γδ T cells 
displayed little or no Kv1.3 current, while ~10% of γδ T cells displayed currents larger 
than 0.5 nA. These results demonstrate that the high-throughput assay presented here 
makes it possible to characterize rapidly cells with heterogeneous phenotypes (e.g. B 




Figure 2.2  |  Histograms of current through Kv1.3 ion channels in lymphocyte subsets 
isolated directly from human blood. Histograms represent the combined totals of Kv1.3 
measurements on individual cells isolated from 3 or more independent blood draws for each 
subtype. (A) CD4+ T cells, N = 1220 total cells measured from 17 independent experiments. (B) 
CD8+ T cells, N = 556 cells from 10 independent experiments. (C) CD19+ B cells, N = 78 cells 
from 3 independent experiments. The dashed blue box indicates the ~5% of measurements with 
large Kv1.3 currents above 1.25 nA. These B cells with large Kv1.3 currents were present in two 
out of the three subjects examined. (D) γδ T cells, N = 84 cells from 3 independent experiments. 
All histograms were constructed with a bin-size of 0.05 nA, and all y-axes display the fraction of 
cells of that subtype (e.g. CD4+ T cells) with Kv1.3 currents in the specified bin. Average Kv1.3 
currents (IKv1.3_avg) for each subtype are listed within each histogram as mean ± standard deviation 




2.4. Quantification of ion current through Kv1.3 ion channels in activated T 
cells  
 To validate the high-throughput assay presented here, we measured the increase 
of Kv1.3 activity in CD4+ and CD8+ T cells after immunologic stimulation. Wulff et al. 
indicated that T cells increased the number of functional Kv1.3 ion channels after 
mitogen stimulation with anti-CD3 antibodies, although the degree of upregulation 
depended on the phenotype of T cell (8). Naïve and central memory T cells modestly 
increased Kv1.3 activity 1.5-fold, while effector memory T cells (Tem) upregulated Kv1.3 
channels 5-fold (8). The reasons for this increase in functional activity of Kv1.3 ion 
channels are not well understood but may be related to regulation of cytokine-specific 
Ca2+ signals in activated T cells (8). 
 Using the high-throughput method to compare CD4+ and CD8+ T cells in parallel, 
we found that the mean whole cell currents through Kv1.3 channels in T cells isolated 
from 10 independent blood draws increased significantly after 72 h of mitogen 
stimulation with anti-CD3 antibodies (Fig. 2.3). The mean Kv1.3 activity from individual 
subjects increased by a factor of 3.0 ± 1.5 in CD8+ T cells (mean ± standard deviation) 
after mitogenic stimulation compared to currents from freshly drawn blood (p = 
0.00001). Correspondingly, mean Kv1.3 activity increased by a factor of 2.5 ± 0.8 in 
CD4+ T cells (p = 0.00001). The mean Kv1.3 activities in CD4+ and CD8+ T cells 
increased to similar extents upon stimulation (p = 0.20). Figure 2.3 shows histograms of 
Kv1.3 currents from individual cells combined from all 10 experiments from T cells from 
freshly drawn blood (797 CD4+ and 541 CD8+ T cells) and from T cells after stimulation 
(823 CD4+ and 888 CD8+ T cells). These histograms show an increased dispersion in 
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Kv1.3 currents after stimulation and highlight the advantages of using high-throughput 
methods to profile the heterogeneous response of primary T cells to stimulation.  
 
Figure 2.3  |  Functional increase of Kv1.3 ion channel activity in stimulated T cells from 10 
independent blood draws. (A) Kv1.3 activity was quantified from freshly drawn blood (labeled 
“initial”, ■), after 72 h culture in the presence of 150 ng mL-1 anti-CD3 antibody (●), and after 72 
h culture without added antibody (no stimulation, ▲). Each point represents mean Kv1.3 current 
in CD4+ (left) or CD8+ (right) T cells from an individual subject. Dashed lines represent averages 
of the 10 experiments (N = 6 for T cells cultured without stimulation), and the error bars show 
standard deviation. (B) Histograms of Kv1.3 currents from 797 CD4+ T cells before (black bars) 
and from 823 CD4+ T cells after 72 h culture with anti-CD3 antibody (red bars). Plots depict the 
fraction of cells in each histogram bin (bin-size = 0.05 nA). (C) Histograms of Kv1.3 currents 
from 541 CD8+ T cells before (black bars) and from 888 CD8+ T cells after stimulation (red bars). 
 
 
 In addition to heterogeneity of responses of individual cells with respect to Kv1.3 
activity, high-throughput functional ion channel recording revealed that blood samples 
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from different individuals (i.e. different human subjects) exhibited surprisingly varied 
Kv1.3 responses to mitogen stimulation (Fig. 2.3A). The largest increase in mean Kv1.3 
activity that we found in a sample from one human subject was a 5.7-fold increase in 
CD8+ T cells; the same subject exhibited a 3-fold increase in CD4+ T cells. In contrast, 
another subject actually exhibited a slight decrease in Kv1.3 activity in CD8+ T cells after 
stimulation. T cells from this subject did not exhibit other characteristics of stimulation 
such as an increase in cell size or upregulation of CD25 or CD26 cell surface markers, 
indicating a deficient response to the activating mitogen.  
 Control experiments with blood samples from all subjects in which we cultured T 
cells without stimulation (i.e. without addition of anti-CD3 antibody) showed no 
significant increase in Kv1.3 activity in either CD4+ or CD8+ T cells (N = 6, p = 0.19 for 
CD4+ T cells, p = 0.97 for CD8+ T cells) (Fig. 2.3A). In summary, these results 
demonstrate three interesting points: (i) the increase in Kv1.3 activity is a direct result of 
T cell stimulation; (ii) CD4+ and CD8+ T cells responded similarly to stimulation despite 
differences in clonality and phenotypes (30, 31); and (iii) the magnitude of Kv1.3 
increase measured using high-throughput electrophysiology varies by individual but 
generally agrees with previous measurements using traditional patch clamping. 
 
2.5. Time-course of Kv1.3 ion channel regulation after T cell stimulation  
 To demonstrate the benefits of the assay presented here, we elucidated time-
courses of the functional Kv1.3 ion channel activity in T cells after stimulation. Previous 
studies have employed manual patch clamping to study the time-dependent changes of 
Kv1.3 activity after mitogenic stimulation in a variety of cell types (25, 32-34). Here, 
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high-throughput screening provided additional insight into the time-courses of Kv1.3 
activity in stimulated human lymphocytes by providing a large number of measurements 
within one hour for statistical analyses and by comparing directly CD4+ and CD8+ 
subsets during the same experiment (i.e. on the same patch plate). We conducted time-
course studies of three subjects who responded strongly to stimulation with anti-CD3 
antibodies (these three subjects are shown in Figure 2.3 with the highest Kv1.3 activity in 
CD8+ T cells). We measured Kv1.3 activity in CD4+ and CD8+ T cells before, as well as 
2 h, 24 h, 48 h, 72 h, and 96 h after stimulation with anti-CD3 antibodies (Fig. 2.4A).  
 Three aspects of this time-course are remarkable. First, 2 h after stimulation, the 
mean Kv1.3 currents decreased by ~50% compared to initial values from blood. This 
reduction in activity possibly resulted from phosphorylation of Kv1.3 channels 
immediately after activation which has been reported to decrease activity (35). Second, 
maximum Kv1.3 activity occurred 48 h after stimulation for two subjects and after 72 h 
for the third subject (mean CD8+ activity increased 4.3 ± 1.2 fold, CD4+ activity 
increased 3.6 ± 0.5 fold). Third, we observed no significant differences between CD4+ 
and CD8+ T cells in average Kv1.3 currents at any time-point (comparing mean values 
obtained from the three subjects at each time-point, minimum p value = 0.19). 
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Figure 2.4  |  Time-courses of functional Kv1.3 activity, as well as other T cell parameters, 
following stimulation with anti-CD3 antibody averaged from 3 subjects. CD4+ T cells are 
depicted as red circles, and CD8+ T cells are depicted as black squares. (A) High-throughput 
measurements of mean Kv1.3 currents in T cells from freshly drawn blood (0 h) and 2 h, 24 h, 48 
h, 72 h, and 96 h after the onset of mitogenic stimulation of PBMCs with 150 ng mL-1 anti-CD3 
antibody. At least 40 CD4+ and 35 CD8+ T cells were averaged at each time point for each 
subject. (B through F) Flow cytometric analysis of other lymphocyte properties following 
stimulation. (B) Mean forward scatter (related to cell volume) (C) Average number of cell 
divisions quantified by CFSE dilution. (D) Percentage of cells with high expression of CD69. (E) 
Mean fluorescence intensity (MFI) of CD25 expression. (F) MFI of CD26 expression. All points 
represent averages of three independent experiments (each experiment was performed on a blood 
sample from a different subject), and the error bars show standard deviation. 
 
 
 To compare the changes in Kv1.3 ion channel activity with changes in other 
parameters of T cells, we measured levels of cell surface markers, proliferation, and cell 
size at each time-point (Fig. 2.4B-F and Fig. 2-App.4). The cell surface marker that 
correlated most strongly with Kv1.3 was CD25, i.e. the α-chain of the IL-2 receptor. Peak 
expression of CD25 occurred at the same time-point as peak Kv1.3 activity, although 
CD25 was upregulated to a greater extent than Kv1.3 ion channels (~30 fold increase in 
mean fluorescence intensity). Forward scatter, which is related to cell volume, also 
correlated strongly with the time-course of Kv1.3 activity. The time-courses of other cell 
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surface markers that are commonly used as activation markers, such as CD69, CD26, and 
CD62L, all displayed distinctly different kinetics of regulation compared to Kv1.3 (Fig. 
2.4D,F and Fig. 2-App.4). Proliferation data, measured in a parallel assay using CFSE to 
quantify the number of divisions of T cells, indicated that T cell proliferation of both 
CD4+ and CD8+ T cells initiated between 48−72 h after the onset of stimulation. Hence, 
proliferation started shortly after the cells reached maximum Kv1.3 activity (Fig. 2.4C). 
The high-throughput assay presented here, therefore, made it possible to place Kv1.3 
activity in the chronology of events during T cell activation. 
 
2.6. Effects of co-stimulation on levels of functional Kv1.3 ion channel 
activity  
 As mentioned previously, the data shown in Figure 2.4 summarized the response 
in Kv1.3 activity of three subjects who responded strongly to stimulation with anti-CD3 
antibodies alone. We also observed subjects who responded weakly to this stimulation 
(Fig. 2.3A). A reason for these differences may be that T cells require two signals for 
effective stimulation, one through the T cell receptor (TCR) and the second through a co-
stimulatory molecule such as CD28 (36). In experiments without co-stimulatory anti-
CD28 antibodies (Figs. 2.3, 2.4), T cells presumably received co-stimulatory signals from 
other cells in culture. We hypothesize that the heterogeneity of Kv1.3 activity in T cells 
upon stimulation may in part be due to varying efficiencies of co-stimulation by other 
cells in the PBMC population. An advantage of the presented method is that the effects of 
different stimulation conditions on Kv1.3 activity can be elucidated rapidly and reliably.  
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 To explore the effects of co-stimulation, we acquired time-courses of Kv1.3 
activity after onset of stimulation with and without added anti-CD28 antibodies from a 
subject who responded weakly to stimulation with anti-CD3 antibodies alone (Fig. 
2.5A,B). Without added anti-CD28 antibodies, Kv1.3 currents increased gradually after 
stimulation; CD4+ currents peaked 72 h after stimulation, and CD8+ currents peaked 96 h 
after stimulation. When we added anti-CD28 antibodies during stimulation of T cells 
from the same subject, we observed markedly accelerated kinetics of Kv1.3 activity. The 
Kv1.3 current peaked 48 h after stimulation for both CD4+ and CD8+ T cells (Fig. 
2.5A,B), and the time-dependent profiles in Kv1.3 activity were now similar to those 
changes of subjects who responded strongly to mitogen stimulation alone (Fig. 2.4A). 
Changes in other T cell properties, such as kinetics of expression of cell surface markers, 
cell size, and proliferation with added anti-CD28 also showed similar correlations to 
Kv1.3 activity as those of subjects that responded strongly to stimulation by anti-CD3 
antibodies alone (Fig. 2.4 and Fig. 2-App.5).  
 To explore the effects of co-stimulation on upregulation of Kv1.3 further, we 
investigated the effects of the concentration of added anti-CD3 antibodies on functional 
Kv1.3 increase after 48 h of stimulation in the presence or absence of a fixed 
concentration of anti-CD28 antibodies (Fig. 2.5C,D). The subject examined had 
previously responded strongly to stimulation with anti-CD3 antibodies alone (Fig. 2.3). 
We observed that maximum Kv1.3 activity occurred at intermediate concentrations of 
added anti-CD3 antibodies (50 and 150 ng mL-1), and that adding anti-CD28 antibodies 
increased Kv1.3 currents by ~30% at these concentrations of anti-CD3 antibodies (Fig. 
2.5C,D). Stimulation with 150 ng mL-1 anti-CD28 antibodies alone did not result in 
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increases in Kv1.3 activity (Fig. 2.5C,D). Interestingly, CD4+ T cells exhibited smaller 
increases in Kv1.3 activity than CD8+ T cells after stimulation with low (5 ng mL-1) and 
high (1000 ng mL-1) concentrations of anti-CD3 antibodies. These results suggest that the 
increase in Kv1.3 channel activity after stimulation depends strongly on the type and 
intensity of this stimulation. These results also identify stimulation conditions (antibody 
concentrations, time-course) for obtaining T cells with maximum Kv1.3 activity.  Such T 
cells might be useful to examine potential drug candidates that block Kv1.3 channels 
(37). 
 
Figure 2.5  |  Functional increase of Kv1.3 ion channel activity in mitogen stimulated T cells 
with or without a co-stimulatory molecule (anti-CD28 antibody). (A) For a subject with a 
previously observed weak response to stimulation with anti-CD3 antibodies alone, time-courses 
of Kv1.3 activity in CD4+ T cells were obtained after stimulation of PBMCs with 150 ng mL-1 
anti-CD3 antibodies alone (■) or with anti-CD3 plus 150 ng mL-1 anti-CD28 antibodies (●). (B) 
Time-courses of Kv1.3 activity in CD8+ T cells in the same experiment as described in (A). (C) 
For a subject with previously measured strong response to anti-CD3 stimulation alone, Kv1.3 
activity in CD4+ T cells was measured after 48 h of stimulation of PBMCs in the presence of 
increasing concentrations of anti-CD3 antibodies with (●) and without (■) 150 ng mL-1 anti-
CD28 antibody. (D) Kv1.3 activity in CD8+ T cells in the same experiment described in (C). All 
points represent averages of Kv1.3 currents from at least 60 T cells; error bars show standard 
error of the mean. 
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2.7. Discussion 
 The expression and function of ion channels in lymphocytes is not only dependent 
on the phenotype of cells but also on their activation status. This characteristic makes ion 
channels especially attractive as selective pharmaceutical targets. In this context, growing 
evidence supports that the activity of ion channels is compromised in different immune-
related pathologies (10, 38); there are, however, inherent difficulties to measure their 
functional activity in freshly isolated cells. Here, we introduce a novel high-throughput 
method that makes the study of specific ion channels in cells of the immune system 
accessible to biochemists, clinicians, and immunologists who often lack the equipment 
and expertise for measuring ion channel activity. 
 This high-throughput assay offers at least three advantages over traditional patch 
clamp techniques. First, it affords a significantly increased number of measurements of 
electrical whole-cell ion currents through individual cells compared to existing 
techniques. We measured as many as 974 lymphocytes within 10 h, a throughput which is 
10 to 50-fold higher than what is possible with manual patch clamp techniques. Large 
numbers of measurements are particularly important in profiling ion channel activity in 
cell populations with heterogeneous phenotypes such as activated CD4+ and CD8+ T 
cells. Moreover, high-throughput measurements allow the detection of small subsets of 
cells within a population that possess high ion channel activity (e.g. B cells or γδ T cells 
directly isolated from blood).  
 Second, the high-throughput assay presented here is rapid (< 1 h) and proceeds in 
a completely automated fashion, including dispensing of cells, establishing seals, 
performing whole-cell voltage-clamp recordings, and processing data. Third, this assay 
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allows direct comparisons of subsets of lymphocytes under the same experimental 
conditions and at the same time-points by examining multiple subsets of cells on the 
same patch plate. By examining Kv1.3 ion channel activity in CD4+ T cells, CD8+ T 
cells, and B cells isolated from human blood by magnetic bead separations, we found that 
the results obtained from the high-throughput electrophysiology method agreed well with 
previously reported data (Fig. 2.2), confirming the reliability and robustness of this 
method. These experiments also revealed that γδ T cells display a different distribution of 
Kv1.3 activity than do CD4+ or CD8+ T cells (Fig. 2.2). These γδ T cells had previously 
not been characterized with respect to the expression of active Kv1.3 channels. γδ T cells 
display specific signaling events that differ from other subsets of lymphocytes (39, 40). 
The results presented here suggest that altered K+ signaling may be one of these different 
signaling events.  
 With respect to immunological implications, we demonstrate the feasibility of 
measuring Kv1.3 ion channel activity as a functional activation marker of T cells. We 
demonstrated that levels of ion currents through Kv1.3 ion channels in human T cells 
peaked between 48 h and 72 h after the onset of mitogenic stimulation and more than 
tripled compared to baseline levels in both CD4+ and CD8+ T cells (Fig. 2.4, 2.5, and 
Figs. 2-App.4, 2-App.5). This increase in Kv1.3 activity depended on both the primary 
stimulatory signal through the TCR as well as co-stimulatory signals. The time-course of 
Kv1.3 activity upon stimulation correlated strongly with expression of CD25 and the 
sizes of T cells (Fig. 2.6). Maximum Kv1.3 levels also occurred shortly before significant 
proliferation of T cells (Fig. 2.6). The immunological basis for the functional increase in 
Kv1.3 activity after stimulation is not well-understood; however, the results presented 
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here, especially the coupling of maximum Kv1.3 activity to the onset of proliferation, 
suggest that the increase in functional levels of Kv1.3 may be cell-cycle related, perhaps 
to ensure proper regulation of the resting potential in daughter cells after division (33). 
 
 
Figure 2.6  |  Time-course of functional Kv1.3 activity in the context of increases of other 
activation markers in T cells. The time-course for Ca2+-signaling (here represented as a spike in 
the intracellular concentration of Ca2+) was inferred from Lewis (7). Data for CD69 expression, 
Kv1.3 activity, CD25 expression, and T cell proliferation were averaged from the three time-
courses shown in Figure 2.4 and from the time-course with added anti-CD28 antibodies in Figure 
2.5. For each individual time-course, values were first averaged between CD4+ and CD8+ T cells 
and normalized between 0% and 100% to account for differences in peak levels between different 
subjects. Figure inspired by Abbas and Lichtman (27). 
 
 
 While the present study focused on lymphocytes, the developed high-throughput 
methodology could in principle be used to screen functional activity of voltage-gated ion 
channels in a range of cell types (e.g. other primary cell types or malignant cells, such as 
lymphoma cells, etc.). For instance, we performed pilot experiments that profiled ion 
channel activity in regulatory T cells (Treg) and dendritic cells (Fig. 2-App.6). The 
requirements for such assays are: (i) preparing a primary cell type in suspension that seals 
well to the planar substrate of the high-throughput patch-clamp device, and (ii) 
identifying a specific blocker of the voltage-gated channel of interest. Several factors 
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affect the sealing of cells to the substrate (41), most notably cell size in relation to the 
size of micropore in the patch plate (small cells require small pores). In addition, surface 
properties of the planar substrate may contribute; modifying the pore size or coating the 
substrate with adhesive molecules, may further increase the number of primary cells that 
can be analyzed successfully in each experimental run. With regards to blockers of ion 
channels, a selection of compounds are available that specifically block various K+, Na+, 
Cl-, and Ca2+ channels (12).  
 High-throughput profiling of ion channels has three limitations compared to 
traditional techniques. First, patch clamping allows for measurements of electrical 
currents through single ion channels (so-called single-channel recordings), mainly 
because of the tight electrical “seals” between the tip of a glass pipette and the attached 
cell (e.g. giga-ohm seal) (17). In contrast, the instrument used in this work typically 
operates with seal resistances between 75-300 MΩ. Potential leak currents are, however, 
subtracted by the leak current compensation of the instrument and by taking differential 
measurements before and after addition of an ion channel blocker (23). Second, the high-
throughput instrument used in this work is not configured to perform measurements of 
ligand-gated ion channels (some existing automated patch clamp technologies do allow 
for measurements of this channel type, albeit at lower throughput (42)). Finally, 
automated patch clamp instruments are currently not widely accessible and are typically 
expensive. Rapid advances in microfabrication (43), microfluidics, and automated patch-
clamp recordings are likely to reduce cost and increase the accessibility to these 




 The functional, high-throughput assay presented here provides a tool to 
investigate the role of ion channels in primary cells, under conditions with different 
degrees of activation, and in physiological or pathological conditions. Importantly, this 
method makes it possible to elucidate profiles of the distribution of ion channel activity. 
We expect this method to serve as a useful and accessible tool for biochemists, cell 
biologists, immunologists, and clinicians to study rapidly and conveniently ion channel 
activity in a range of primary cell types. The ensuing insight based on functional 
activities of ion channel proteins that are involved in cell signaling and immune cell 
activation may lead to a better understanding of the role of ion channels in physiology, 
immune responses, and human disease. 
 
 
Chapter 2 Appendix 
 
2-App.Methods.  Supporting Methods  
 Cell culture and separations. To separate subsets of lymphocytes from whole 
blood, we first isolated peripheral blood mononuclear cells (PBMCs). We centrifuged 
whole blood at 700 × g for 20 min to isolate the intermediate “buffy coat” layer 
containing white blood cells. A subsequent density gradient centrifugation (Histopaque, 
Sigma-Aldrich, St. Louis, MO) at 700 × g for 20 min allowed separation of PBMCs from 
this buffy coat layer. Isolated PBMCs were washed twice in wash buffer, defined here as 
Dulbecco’s modified phosphate buffered saline without Ca2+ or Mg2+ (D-PBS, 
Invitrogen, Carlsbad, CA) and supplemented with 2% (v/v) fetal bovine serum (FBS, 
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Mediatech, Herndon, VA). To select for particular subsets of lymphocytes, we separated 
PBMCs using magnetic beads coated with antibodies against either CD4, CD8, CD19 
(for B cells), or the γδ T cell receptor (Miltenyi Biotec, Auburn, CA). Briefly, we added 
50 µL of bead solution to 350 µL of PBMCs suspended in wash buffer and incubated for 
15 min at room temperature. We then passed labeled cells through a paramagnetic 
column (Miltenyi Biotec) and collected positively-labeled cells which were retained in 
the column. After magnetic separations in columns, we stored cells either at 4° C for flow 
cytometry analysis or prepared them immediately for high-throughput electrophysiology 
measurements. 
 To culture and stimulate cells, we first washed the separated PBMCs in culture 
media, here defined as RPMI-1640 medium (ATCC, Manassas, VA) supplemented with 
10% (v/v) FBS, 150 U mL-1 penicillin, 150 µg mL-1 streptomycin (pen-strep, Invitrogen), 
and 55 µM 2-mercaptoethanol (Invitrogen). To stimulate T cells, we added soluble 
monoclonal mouse anti-human CD3 antibody (clone UCHT1, BD Biosciences, San Jose, 
CA) at indicated concentrations in culture media. For co-stimulation experiments, we 
additionally added 150 ng mL-1 soluble monoclonal anti-CD28 antibody from mouse 
(clone CD28.2, BD Biosciences) to PBMCs in suspension. Cells with added antibodies 
for stimulation were seeded in tissue culture flasks (8 mL into T25 flasks, BD 
Biosciences) at a concentration of 1×106 cells mL-1 and cultured at 37° C in an 
atmosphere of 5% CO2, for 72 h unless otherwise noted. After culture, we washed 
PBMCs twice in wash buffer and then used magnetic bead separations to isolate 
stimulated CD4+ and CD8+ T cells. These stimulated cells were either stored at 4° C for 
flow cytometry or prepared immediately for high-throughput electrophysiology. 
 56
 Wash protocols for the high-throughput electrophysiology instrument. After 
measuring Kv1.3-specific currents in all 384 wells of the patch plate, we used the 
automated wash protocols of the IonWorks HT system to flush the internal fluidics and 
microfluidics array for dispensing drugs to each well of the “patch plate”. The sequence 
of wash steps consisted of a flush with 5% Hellmanex II (Hellma GmbH & Co. KG, 
Müllheim, Germany) in H2O followed by a flush with distilled H2O (repeat sequence 
twice).  We also washed the electrode array by soaking the electrode tips in 2.5% 
Hellmanex II in H2O for 60 s followed by a final soak in D-PBS for 120 s. 
 Algorithms to quantify Kv1.3-specific currents. We developed custom 
computer software using the PERL language to quantify specifically the ion current 
passing through Kv1.3 ion channels. The algorithm first automatically filtered out cells 
that did not maintain stable seals with the micropore in each well of the patch plate. For a 
cell to be considered “stable” and to yield a valid whole-cell recording, we imposed two 
criteria: (i) the cell had to maintain a seal resistance with the micropore of the patch plate 
of at least 75 MΩ throughout the experiment (including after addition of the compound); 
and (ii) the magnitude of the seal resistance had to be constant within ± 25% from pre-
compound to post-compound measurements. 
 For cells with valid seals, we quantified Kv1.3-specific currents by subtracting the 
post-compound (i.e. post blockage with ShK-F6CA) current from the pre-compound 
current (Fig. 2-App.3B). The PERL computer algorithms computed the pre-compound 
current by determining the maximum current (averaged during a 1-ms “time-window”) 
after the depolarizing pulse and subtracting an average of the current before the 
depolarizing pulse (baseline current). The post-compound current consisted of 
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quantifying, again, the average current over a 1 ms interval. This interval was taken at the 
exact same time after applying the depolarizing pulse as the time interval from the pre-
compound recording. The algorithm then, again, subtracted an average of the current 
before the depolarizing voltage pulse (baseline current). Finally, the algorithm computed 
the Kv1.3-specific current from the difference between the pre- and post-compound 
currents (Fig. 2-App.3). We confirmed the accuracy of these algorithms in each 
experiment by viewing the largest currents in each experiment graphically, but all 
computations of currents were performed automatically by the PERL programs to ensure 
unbiased, reliable, and automated data analysis. 
 Flow cytometry assays. We performed flow cytometry analysis using a four-
color flow cytometer (FACScalibur, Becton Dickinson, Franklin Lakes, NJ) with 
CellQuest software. Cells were stained with antibodies against the following antigens (all 
from BD Biosciences) conjugated to either the fluorophore allophycocyanin (APC) or 
phycoerythrin (PE): CD4-APC, CD8-APC, CD8-PE, CD19-PE, CD25-PE, CD26-PE, 
CD62L-PE, CD69-PE, and CD69-APC. All staining, incubation (for 30 min), and wash 
procedures occurred at 4°C using wash buffer. For each type of surface marker, we 
measured forward scatter, side scatter, and fluorescence intensity from at least 5,000 cells 
(typically from over 10,000 cells). All cytometer settings (compensation and detector 
voltages) remained constant for all experiments. We typically quantified mean 
fluorescence intensity (MFI) for all cells gated (i.e. selected) as lymphocytes based on 
size (forward scatter) and complexity (side scatter) using analysis software (WEASEL, 
The Walter and Eliza Hall Institute, Parkville, Australia). For cells stained with CD69, 
we determined the percentage of cells with “high” levels of CD69 (CD69+) by computing 
 58
the percentage of cells with fluorescence intensities above the background fluorescence 
levels of unstained cells. 
 CFSE assays to quantify proliferation in CD4+ and CD8+ T cells. To quantify 
the proliferation of T cells, we measured the levels of carboxyfluorescein diacetate 
succinimidyl ester (CFSE) in individual T cells. Labeling cells with CFSE made it 
possible to determine T cell proliferation by flow cytometry, as cells evenly split their 
concentration of CFSE when they divided. We performed experiments with cells labeled 
with CFSE in parallel to experiments with unlabeled cells for high-throughput 
electrophysiology measurements because electrophysiology experiments required a 
significantly higher number of cells than CFSE experiments. We stained cells with 0.25 
µM CFSE according to instructions from the manufacturer (Invitrogen). Stained 
populations of cells were seeded into flat-bottom 96-well plates using the same cell 
density, media, and stimulation conditions as the corresponding cultures for Kv1.3 
measurements.  
 Before analysis, we labeled CFSE-stained cells with either anti-CD4-APC or anti-
CD8-APC antibodies to observe specifically the proliferation in those subsets. We used 
APC-labeled antibodies to avoid “interference” between APC and CFSE (measured using 
the FITC excitation and detection settings) during the detection by flow cytometry. To 
quantify proliferation from the resulting flow cytometry data, we performed the following 
three steps: first, we selected (or gated) for lymphocytes based on the size (forward 
scatter) and complexity (side scatter) of the cells in the cytometer; second, among gated-
lymphocytes, we selected for cells with high levels of APC fluorescence, representing 
CD4+ or CD8+ T cells; and third, for gated CD4+ or CD8+ T cells, we determined the 
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percentage of cells in each of the clearly-defined CFSE “peaks”. Each peak corresponded 
to cells that divided 0×, 1×, 2×, 3×, 4×, etc., respectively. Determining the percentages of 
cells that divided a known number of times allowed calculation of the average number of 
cell divisions for a specific cell population. 
 Statistical Analyses. We calculated all P-values using a two-sample Student’s t-
test (Origin, Northampton, MA). Means and standard deviations are clearly indicated 
throughout the text, with all standard deviations calculated using sample standard 
deviation. In indicated cases, we used standard error of the mean (defined as standard 
deviation divided by N ) to depict potential errors in mean values of Kv1.3 activity 
determined from individual high-throughput electrophysiology experiments. 
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2-App.Table. Throughput of automated ion channel experiments using lymphocyte 
subsets isolated from human blood. 
lymphocyte 
subset 
percentage of wells in 





successful cells, MΩ 
main reason for 
unsuccessful wells 
CD4+ T cells 42 ± 9 134 ± 21 lost/low seals after compound addition 
CD8+ T cells 32 ± 9 124 ± 23 lost/low seals after compound addition 
B cells 15 ± 6 123 ± 6 lost/low seals after compound addition 
γδ T cells 25 ± 3 116 ± 4 
low seal resistance 
between cell and 
microwell 
stimulated 
CD4+ T cells* 46 ± 12 152 ± 23 
no seal between cell and 
microwell 
stimulated 
CD8+ T cells* 50 ± 13 146 ± 23 
no seal between cell and 
microwell 
All subsets measured using half of a 384-well patch-plate.   
Values represent average ± standard deviation of mean values from individual subjects involving the 
indicated subtype (N = 17 for CD4+ T cells, N = 10 for CD8+ T cells, N = 3 for B cells, N = 3 for γδ T cells, 
N = 10 for stimulated CD4+ T cells, and N = 10 for stimulated CD8+ T cells). 
* T cells stimulated for 3 d with 150 ng mL-1 anti-CD3 antibodies. 
 
 
There may be several reasons for the different throughputs of the various subsets 
of lymphocytes using the IonWorks HT high-throughput electrophysiology system. Cell 
size may affect the stability of lymphocytes attached to the micropores of the “patch 
plate”. Stimulated T cells, with an average of ~1.5 times the diameter of resting T cells 
from blood, exhibited higher average seal resistances than resting T cells (p < 0.05 for 
both CD4+ and CD8+ T cells). These stimulated T cells were also ~20% less likely than 
 61
resting T cells to lose their seals after addition of the ShK-F6CA compound to block 
Kv1.3 channels (p < 0.01 for both CD4+ and CD8+ T cells).  
A second reason for the different throughputs may be related to surface 
morphology of the lymphocyte subset. CD4+ and CD8+ T cells isolated from blood, 
which have very similar sizes and which were always measured in parallel on the same 
patch plate, exhibited different throughputs in high-throughput electrophysiology 
experiments. CD4+ T cells showed ~10% higher throughput than CD8+ T cells (p < 0.01), 
as CD4+ T cells were 15% more likely to contact the micropore and 10% more likely to 
have sufficiently high seals after initially contacting the micropore than CD8+ T cells. 
CD4+ and CD8+ T cells were equally likely to lose seals after compound addition. 
Properties of CD4+ and CD8+ T cells that may contribute to the initial sealing to the 
micropore might include differences in phenotypes, expression of certain cell surface 
molecules, and perhaps differences in mechanical properties. 
An interesting finding in the analysis of throughputs of different lymphocyte 
subsets is that B cells and γδ T cells isolated from blood had significantly lower 
throughput than CD4+ or CD8+ T cells. γδ T cells were especially likely to form low and 
insufficient seals with the micropores but otherwise behaved similarly to CD4+ T cells. B 
cells, which exhibited the lowest throughput of all cell types measured, were the least 
likely subset to initially contact the micropore and was the most likely subset to lose seals 
after addition of compound.  The reasons for this instability may be related to 
morphological or mechanical properties of B cells. Modifications to the patch plates, 
either by having smaller diameters of micropores or by coating the plates with adhesive 
molecules, may help to increase seal resistances and stability and increase throughputs 
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for all cell types. The observed differences in behavior of different lymphocytes attached 
to micropores may, however, allow insights into the mechanical properties of 
lymphocytes and may provide a platform for rapid screening of drug compounds or 
molecules that affect the cytoskeleton and mechanical stability of primary cells. 
 








Figure 2-App.1  |  Confirming full blockage of Kv1.3 ion channels. This graph quantifies the 
correlation of the recorded whole-cell ion current after addition of ShK-F6CA (post-compound 
currents) as a function of the ion current before addition of the blocker (pre-compound currents). 
The recorded currents were obtained from CD8+ T cells from the time-course shown in Figure 
2.5B in the main text (stimulation with both anti-CD3 and anti-CD28 antibodies, number of CD8+ 
T cells, N = 342 from the five time-points). The red line represents a linear best fit of to the data 
(slope = −0.0001, R2 = 2 × 10-7). The slope of this line was zero, and the absence of correlation of 
the data indicates that the magnitude of the post-compound currents was not dependent on the 
magnitude of the pre-compound currents. This absence of correlation demonstrates full-block of 
Kv1.3 ion channels. 
 63
2-App.2. Specificity of the high-throughput electrophysiology method for 
Kv1.3 ion channel activity 
 
Figure 2-App.2  |  Specificity of the high-throughput electrophysiology method for Kv1.3 ion 
channel activity. This figure depicts the blockage of ion current through stimulated CD8+ T cells 
by different drug compounds. Electrical currents recorded before addition of the drug compound 
(black line) were compared to currents through the same cell after 3 min incubation with the 
respective drug compound (red lines). Compounds tested included the following known blockers 
of Kv1.3 ion channels at concentrations well above their IC50 value for Kv1.3 ion channels: (A) 
72 nM ShK-F6CA (IC50=48 pM); (B) 160 nM margatoxin (IC50=110 pM); (C) 250 nM Psora-4 
(IC50=3 nM), which was initially dissolved in DMSO before dilution in D-PBS. For these 
compounds, the residual electrical current after addition of the compound (i.e. in the presence of 
the blocker) was severely attenuated and did not display the time-dependent de-activation that is 
characteristic of Kv1.3 ion channels.3 These residual currents after addition of blocker were 
mostly due to a “leak” current from imperfect electrical seals between the cell and the micropore 
in the patch plate. A part of these currents may have also been due to the presence of other 
voltage-gated ion channels than Kv1.3 channels. The following compounds and solutions that are 
known not to block Kv1.3 ion channels were also tested: (D) D-PBS; (E) 0.33% DMSO in D-
PBS; (F) 150 nM TRAM-34, which was initially dissolved in DMSO before dilution in D-PBS. 
The example of TRAM-34 is particularly important because TRAM-34 blocks the calcium-gated 
potassium ion channel KCa3.1 (IC50=20 nM), which is the other significant potassium ion 
channel in T cells (besides Kv1.3). For each of these conditions, the electrical current after 
addition of the compounds (or solution) was not attenuated and still displayed time-dependent de-
activation of Kv1.3 channels. The observation that TRAM-34 did not block the electrical current 
through T cells in this assay suggests that most of the K+ current measured in this assay was due 
to Kv1.3 ion channels. This result, in combination with using the ShK peptide, a blocker highly 
specific for Kv1.3 channels, confirms that the high-throughput assay presented here is specific for 
Kv1.3 ion channels. Note that all compounds were dispensed using the integrated fluidics of the 
high-throughput electrophysiology device, and all concentrations of compounds refer to final 
concentrations in the microwells. All graphs are representative of measurements from at least 20 
cells for each compound or solution. 
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Figure 2-App.3  |  Algorithms to quantify Kv1.3-specific currents. This figure shows a 
graphical representation of the data processing algorithms used to quantify Kv1.3-specific 
currents. (A) Schematic of the patch-plate with CD4+ T cells measured on the left half (192 wells) 
and CD8+ T cells measured on the right half of the plate. Only cells with sufficiently high (>75 
MΩ) and stable seals between the cell and micropore were included for analysis (such wells of 
the micropore are depicted in yellow). Wells in which no cell sealed to the micropore (red squares 
without an “×”) or wells in which cells did not have sufficiently high or stable seals (red squares 
with an “×”) were excluded from further analysis. (B) Application of a voltage-pulse to quantify 
the ion currents before (pre-compound current) and after addition of a highly-specific blocker 
(ShK) of Kv1.3 ion channels (post-compound current). All current amplitudes (represented by the 
vertical arrows) were obtained by subtracting the current before application of the pulse from the 
maximum current after addition of the pulse (all current values were obtained by averaging over a 
1-ms window). (C) Graphical example of a “Kv1.3-speicific” current trace, obtained by 
subtracting the post-compound current from the pre-compound current at each time-point. The 
values displayed throughout the text, however, represent the pre-compound current minus the 
post-compound current, as computed in panel (B). All determinations of sufficiently high and 
stable seals as well as quantifying of amplitudes of Kv1.3-specific currents were computed 
automatically using custom-written PERL algorithms. 
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2-App.4. Time-courses of Kv1.3 activity using three human subjects. 
 
Figure 2-App.4  |  Individual time-courses of functional Kv1.3 activity after mitogenic 
stimulation in three different subjects. This figure shows individual time-courses of functional 
Kv1.3 activity, as well as other T cell parameters, for three subjects following mitogenic 
stimulation with anti-CD3 antibodies (Fig. 2.4 in main text). CD4+ T cells are depicted as red 
circles, and CD8+ T cells are depicted as black squares. Time-courses for each of the three 
individual subjects are separated into three columns (all time-courses in the same column are 
from the same subject), with each row depicting a time-course of a single T cell parameter. (A) 
High-throughput measurements of mean Kv1.3 currents in T cells from freshly drawn blood (0 h) 
and 2 h, 24 h, 48 h, 72 h, and 96 h after the onset of mitogenic stimulation of isolated PBMCs 
with 150 ng mL-1 anti-CD3 antibody. Error bars represent standard error of the mean. (B through 
G) Flow cytometric analysis of other lymphocyte properties following stimulation. (B) Mean 
forward scatter (related to cell volume). (C) Percentage of cells expressing high levels of CD69. 
(D) Mean fluorescence intensity (MFI) of CD25 expression. (E) MFI of CD26 expression. (F) 
MFI of CD62-L expression. (G) Average number of cell divisions quantified by CFSE dilution.    
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2-App.5. Time-course of functional Kv1.3 activity after stimulation with both 







Figure 2-App.5  |  Time-course of functional Kv1.3 activity after stimulation with both anti-
CD3 and anti-CD28 antibodies. This figure shows time-courses of functional Kv1.3 activity, as 
well as other T cell parameters, following stimulation with both anti-CD3 and anti-CD28 
antibodies (Fig. 2.5A,B in the main text). CD4+ T cells are depicted as red circles, and CD8+ T 
cells are depicted as black squares. (A) High-throughput measurements of mean Kv1.3 currents in 
T cells from freshly drawn blood (0 h) and 2 h, 24 h, 48 h, 72 h, and 96 h after the onset of 
mitogenic stimulation of isolated PBMCs with 150 ng mL-1 anti-CD3 antibody and 150 ng mL-1 
anti-CD28 antibody. Error bars represent standard error of the mean. (B) Largest single Kv1.3 
current measured, here denoted as “maximum Kv1.3 current”. (C) Average cell diameter, 
measured immediately prior to high-throughput electrophysiology experiments using a Coulter 
counter. (D through I) Flow cytometric analysis of other lymphocyte properties following 
stimulation. (D) Percentage of cells expressing high levels of CD69. (E) Mean fluorescence 
intensity (MFI) of CD25 expression. (F) MFI of CD26 expression. (G) MFI of CD45-RO 
expression. (H) MFI of CD62-L expression. (I) Average number of cell divisions quantified by 
CFSE dilution.  
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Figure 2-App.6  |  Distribution of Kv1.3 ion currents in regulatory T cells and dendritic 
cells. This figure displays histograms of ion current from pilot experiments that measured Kv1.3 
activity in CD4+ T cells, regulatory CD4+ T cells (Treg) isolated from human peripheral blood and 
cultured for 24 h, as well as dendritic cells cultured for 7 d. (A) Cultured CD4+ T cells, N = 85 
total cells measured from one experiment (mean ion current through Kv1.3 ion channels = 0.21 ± 
0.11 nA, mean ± standard deviation). (B) Cultured Treg cells, N = 32 (mean Kv1.3 ion current = 
0.13 ± 0.12 nA). Note that the CD4+ T cells in panel (a) and the Treg cells in panel (b) were 
isolated from the same individual and separated and cultured under the same conditions. Treg cells 
and CD4+ T cells were initially separated from freshly isolated PBMCs using magnetic bead kits 
(Miltenyi Biotec, using the CD4+/CD25+/CD127dim/- kit for Tregs). CD4+ T cells and Treg cells, with 
magnetic beads still attached, were cultured for 24 h in culture media supplemented with IL-2 (20 
U mL-1, Sigma), TGF-beta (2 ng mL-1, Sigma), IL-10 (5 µg ml-1, eBioscience, Inc., San Diego, 
CA), and anti-CD3 antibodies (clone OKT3, 50 ng mL-1, eBioscience). Note that the culture 
conditions for the CD4+ T cells shown here and the Treg cells shown here were significantly 
different from the culture conditions for cells in the main text. Here conditions were used to 
sustain cells rather than activate them. (C) Dendritic cells, N = 67 cells from one experiment 
(mean Kv1.3 ion current = 0.06 ± 0.09 nA). Dendritic cells were prepared by culturing monocytes 
isolated by a magnetic bead kit (Miltenyi Biotec) in culture media for 7 d in the presence of 20 ng 
mL-1 GMC-SF (Sigma) and 20 ng mL-1 IL-4 (eBioscience). 
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Functional Regulation of Kv1.3 Ion Channels in Human T Lymphocytes 
 
 This chapter examines the effects of immunosuppressive drugs on the activity of 
Kv1.3 ion channels in T cells upon stimulation. While activated T cells with high Kv1.3 
activity have been implicated in the pathogenesis of several autoimmune diseases, the 
pathways that lead to this high Kv1.3 activity have not been explored. In this work, a 
recently developed, automated, high-throughput assay afforded quantification of 
functional levels of Kv1.3 ion channels in human CD4+ T cells following mitogenic 
stimulation of peripheral blood mononuclear cells (PBMCs). We pre-treated PBMCs with 
either cyclosporin A (CsA), rapamycin, or tyrphostin AG-490 (an inhibitor of Janus 
kinases (Jak)-2 and Jak-3). All three drugs suppressed Kv1.3 activity after stimulation 
with anti-CD3 antibodies (aCD3) alone. Interestingly, only tyrphostin AG-490 fully 
inhibited the increase in Kv1.3 activity when recombinant interleukin (IL)-2 was present 
during stimulation with aCD3. In addition, both recombinant IL-2 and IL-15, but not IL-6 
or IL-10, directly led to increased Kv1.3 activity in the absence of stimulation with 
aCD3. This work suggests that functional levels of Kv1.3 ion channels are regulated 
through signaling through the IL-2 receptor, mediated by Jak-3 pathways. 
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3.1. Introduction     
 Human T cells contain two major types of plasma membrane K+ channels, the 
voltage gated Kv1.3 channel and the Ca2+-activated KCa3.1 channel. These channels play 
important roles in processes involving Ca2+-signaling (1-3). Kv1.3 ion channels, in 
particular, regulate the resting membrane potential of human T cells and allow for 
sustained Ca2+-influx after T cell stimulation (4-6). The numbers of Kv1.3 ion channels 
per T cell increases after stimulation by a factor of 2-5, depending on cell phenotype and 
stimulation techniques (7-9). Effector memory T cells experience the largest increase in 
Kv1.3 activity, although the reasons for this increase are not known (8). 
 Recently, T cells with high numbers of Kv1.3 channels have been implicated in 
the pathogenesis of several autoimmune diseases (10). The Chandy and Calabresi groups 
found that disease-associated, autoreactive T cells isolated from patients with multiple 
sclerosis (MS), type-1 diabetes, and rheumatoid arthritis (RA) had elevated Kv1.3 
activity after activation compared to autoreactive T cells from controls (8, 11). In 
addition, Rus et al. showed that T cells in inflammatory infiltrates in the brains of post-
mortem MS patients displayed high numbers of Kv1.3 ion channels (12). Drug candidates 
that specifically block Kv1.3 ion channels ameliorated or delayed onset of symptoms in 
animal models of MS, RA, type-1 diabetes, and allergic contact dermatitis (11, 13, 14). 
The Kv1.3 ion channel, therefore, is a promising target for treating and studying the 
molecular mechanisms of autoimmune diseases (15). 
 Despite the disease-relevance of T cells with high levels of Kv1.3 activity, little is 
known about the cellular and biochemical pathways that lead to this increased activity 
after T cell activation. Previously, Beeton et al. examined the effects of 
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immunosuppressive drugs CsA (100 nM) and staurosporine (10 nM) on the increase of 
Kv1.3 activity after stimulation of a rat T cell line specific for myelin basic protein (16). 
Both drugs, which affect early events in T cell stimulation leading to transcription of IL-
2, decreased Kv1.3 activity by ~60% (16). It is not clear, however, whether this decrease 
was due to the direct effects of the immunosuppressive drugs or due to the suppression of 
other downstream molecules that may regulate Kv1.3 activity. One likely reason for the 
lack of information about pathways regulating Kv1.3 activity may be due to the 
difficulties associated with measuring functional levels of ion channels in T cells. 
Previous studies have employed manual patch-clamping, which, while extremely 
sensitive, is serial, has low-throughput, and requires significant expertise.  
 Here, we use a recently-developed high-throughput assay for measuring voltage-
gated ion channels in human T cells to examine pathways that lead to increased Kv1.3 
activity after stimulation. This assay afforded the following characteristics: (i) automated 
patch clamp of 100-200 T cells in 1 h; (ii) specificity for Kv1.3 ion channels; and (iii) 
ability to compare different T cell populations in parallel (7, 17). Previously, this assay 
enabled the study of the heterogeneous, time-dependent changes in Kv1.3 activity in T 
cells after mitogenic stimulation (7). In the present study, we examine the effects of 
immunosuppressive drugs, acting at different points in the signaling cascade, on Kv1.3 
activity after mitogenic stimulation (18). We also explore the effects of pro- and anti-
inflammatory cytokines on Kv1.3 activity. The results presented here suggest that Kv1.3 
is regulated by IL-2-dependent pathways and may provide insight towards disrupting 




3.2. Materials and Methods 
 
 Human subjects. We obtained peripheral venous blood from healthy subjects 
using protocols reviewed and approved by the Institutional Review Board at the 
University of Michigan. All subjects had previously exhibited a proliferative response of 
T cells upon stimulation with mitogenic anti-CD3 antibodies (7). 
 Cell culture and stimulation of T cells. We isolated peripheral blood 
mononuclear cells (PBMCs) from whole blood using density gradient centrifugation 
(Histopaque 1077 and 1119, Sigma-Aldrich, St. Louis, MO). We suspended isolated 
PBMCs at 1 × 106 cells mL-1 in culture media, defined as RPMI-1640 medium (ATCC, 
Manassas, VA) supplemented with 10% (v/v) fetal bovine serum (FBS, Mediatech, 
Herndon, VA), 100 U mL-1 penicillin, 100 μg mL-1 streptomycin (pen-strep, Invitrogen), 
and 55 μM 2-mercaptoethanol (Invitrogen) and then seeded PBMCs into 24-well plates 
(1 mL per well, BD Biosciences, San Jose, CA). For studies involving 
immunosuppressive drugs, we added one of the following molecules at concentrations 
specified in the text: cyclosporin A (CsA, Sigma-Aldrich), rapamycin (Sigma-Aldrich), 
or tyrphostin AG-490 (Sigma-Aldrich). Final concentrations of dimethyl sulfoxide 
(DMSO) were below 0.05% except in the case of 100 μM tyrphostin AG-490 (0.2% 
DMSO); we correspondingly added 0.2% DMSO into culture for all experiments with 
tyrphostin AG-490, including control experiments. Cells were incubated with drugs for 
30 min at 37° C in 5% CO2. 
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 After pre-incubation with immunosuppressive drugs, we stimulated PBMCs by 
adding 150 ng mL-1 anti-human CD3 monoclonal antibody from mouse (aCD3, clone 
UCHT1, BD Biosciences), 150 ng mL-1 anti-human CD28 monoclonal antibody from 
mouse (aCD28, clone CD28.2, BD Biosciences), or 1000 U mL-1 recombinant human 
interleukin (IL)-2 (rIL-2, eBioscience, San Diego, CA), as specified in the text. For 
experiments with exogenous cytokines, we added the following concentrations of 
recombinant human cytokines (all from eBioscience): 1000 U mL-1 IL-15 (rIL-15), 1000 
U mL-1 IL-6 (rIL-6), or 100 U mL-1 IL-10 (rIL-10). Cells were then cultured at 37° C in 
5% CO2 for ~64 h. For experiments measuring ion channel activity, we separated CD4+ T 
cells from stimulated PBMCs using magnetic beads coated with antibodies against CD4 
(Miltenyi Biotech, Auburn, CA) according to the manufacturer’s instructions with minor 
modifications (7).  
 High-throughput profiling of Kv1.3 ion channels in CD4+ T cells. We used an 
IonWorks HT high-throughput electrophysiology instrument (MDS Analytical 
Technologies, Sunnyvale, CA) made available via collaboration with the original 
developers of the technology (Essen Instruments, Ann Arbor, MI). Detailed methodology 
and validation of this technique for human lymphocytes can be found elsewhere (7). 
Briefly, we suspended isolated CD4+ lymphocytes in Dulbecco’s phosphate buffered 
saline (D-PBS) with Ca2+ and Mg2+ at a concentration of 5 × 105 to 1 × 106 cells mL-1 and 
stored the cells at room temperature for 30 min prior to electrophysiology experiments. 
The IonWorks HT instrument automatically dispensed the cells into a 384-well planar 
substrate (each well contained a single micropore to which a single T cell was attached 
via suction), and then gained intracellular access to the attached T cell by adding a 
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perforating agent (amphotericin B, 100 μg mL-1, Sigma-Aldrich) in the intracellular 
recording solution (100 mM K+ D-gluconic acid, 50 mM KCl, 3 mM MgCl2, and 5 mM 
EGTA pH 7.3). A parallel array of 48 Ag/AgCl electrodes recorded the whole-cell 
electrical currents through the attached T cell in each well upon application of a 
depolarizing step pulse from −80 mV to + 40 mV for 300 ms. To render the assay 
specific for Kv1.3 ion channels, integrated fluidics within the IonWorks HT instrument 
then added a specific blocker of Kv1.3 ion channels, 6-FAM-AEEAc- Stichodactyla 
helianthus neurotoxin peptide (ShK, Bachem Biosciences, King of Prussia, PA) at a final 
concentration of 72 nM to each well of the patch plate (7). After 3 min incubation to 
block all Kv1.3 ion channels, electrical currents from the attached cells were measured 
again using the same voltage protocols as described above. We developed automated 
computer algorithms to compute the Kv1.3-specific current, which we defined as the 
difference between the pre-compound (pre-ShK) and post-compound (post-ShK) currents 
in cells that maintained stable seals resistances > 75 MΩ (7). Typically, we examined 
four different CD4+ T cell conditions (e.g. different concentrations of drugs in culture) 
per 384-well plate, obtaining successful Kv1.3 measurements in 25-60 CD4+ T cells for 
each condition. 
 Flow cytometry assays for measuring T cell activation markers. We measured 
expression of T cell activation markers using a four-color flow cytometer (FACScalibur, 
Becton Dickinson, Franklin Lakes, NJ). PBMCs cultured in flat-bottom 96-well plates 
(treated exactly as PBMCs for Kv1.3 measurements) were stained with anti-human CD4 
antibodies conjugated to allophycocyanin (APC) plus antibodies conjugated with 
phycoerythrin (PE) against one of the following three human antigens: CD69, CD25, or 
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CD26 (all antibodies from BD Biosciences). All staining, incubation (30 min), and wash 
procedures occurred at 4° C using D-PBS (without Ca2+ or Mg2+) supplemented with 2% 
FBS. We typically quantified mean fluorescence intensity (MFI) of PE-labeled antibodies 
for at least 10,000 cells gated as live cells on the basis of forward- and side-scatter and 
also gated for high expression of CD4 (Weasel analysis software, The Walter and Eliza 
Hall Institute, Parkville, Australia).  
 Quantitative real-time RT-PCR for measurements of Kv1.3 mRNA. We used 
two-step quantitative real-time RT-PCR (qRT-PCR) to quantify expression of Kv1.3 
mRNA. We separated ~1 × 106 CD4+ T cells from PBMCs stimulated for either 24 or 48 
h, as described above and extracted total mRNA using a commercially available kit 
(RNeasy Mini, Qiagen, Valencia, CA). Absorbance readings confirmed A260/A280 
ratios between 1.6 and 2.0 for all samples. We reverse transcribed 250 ng mRNA for each 
sample (QuantiTect reverse transcription kit, Qiagen) and immediately diluted the 
resulting cDNA by a factor of two. For qRT-PCR reactions (25 μL reaction volumes in 
96-well plates using an Applied Biosystems ABI7500 thermal cycler), we used SYBR 
green (QuantiTect SYBR green PCR kit, Qiagen) as a reporter dye for double stranded 
DNA synthesized from primer pairs to the following human genes: KCNA3, IL-2, 
GAPDH, or RPLP0 (using pre-designed QuantiTect primers from Qiagen). After 40 
thermal cycles, we determined the cycle threshold (CT) values and calculated expression 
levels using comparative CT methods. We quantified expression levels of IL-2 and 
KCNA3 relative to either GAPDH or RPLP0 and normalized them to the expression 
levels of CD4+ T cells cultured without added stimulation. 
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 Statistical analyses. We used the Kolmogorov-Smirnov test to compare 
distributions of Kv1.3 currents in CD4+ T cells which were stimulated under different 
conditions (R Project for Statistical Computing). All p values and significance levels are 
specified in the text. To represent distributions of Kv1.3 currents in the figures 
throughout the text, we used box plots with the following characteristics: whiskers 
represent the 10th and 90th percentile of Kv1.3 values in the distributions; the large box 
represents the values between the 25th and 75th percentile; the solid line within the box 
represents the median value; and the dark square depicts the mean value. 
 To obtain IC50 values of half-maximal suppression of Kv1.3 activity after 
stimulation with various concentrations of immunosuppressive drugs, we fit normalized 
data to the logistic equation. 
 
3.3. CsA attenuates the increase in Kv1.3 activity after stimulation except 
with strong CD28 co-stimulation 
 To test the role of early signaling events after stimulation through the TCR-CD3 
complex on regulating Kv1.3 activity, we measured the effects of cyclosporin A (CsA), a 
commonly used immunosuppressive drug. CsA inhibits calcineurin and blocks expression 
of IL-2 and other cytokines when T cells are stimulated via the TCR-CD3 complex (19). 
We examined CD4+ T cells isolated from human PBMCs that were pre-treated with CsA 
and stimulated with mitogenic antibodies for ~64 h. In a previous study, human T cells 
reached maximum Kv1.3 activity between 48 and 72 h after stimulation, depending on 
the subject (7). 
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 CsA inhibited the increase of Kv1.3 activity after stimulation with anti-human 
CD3 monoclonal antibodies (aCD3) in a dose-dependent manner (IC50 = 75 nM, Fig. 
3.1A). CD4+ T cells treated with 400 nM and 1000 nM CsA showed no significant 
differences in Kv1.3 activity compared to T cells cultured without any stimulation 
(p=0.99 for both concentrations, Fig. 3.1D). A comparison of Kv1.3 activity to other T 
cell activation markers showed that CsA inhibited expression of CD26 (Fig. 3.1B), 
expansion of cell volume (Fig. 3.1C), and T cell proliferation after stimulation with aCD3 
alone.  
 When we stimulated PBMCs in the presence of co-stimulatory anti-human CD28 
monoclonal antibodies (aCD28) in addition to aCD3, however, CsA no longer inhibited 
the increase in Kv1.3 activity (Fig. 3.1A). Kv1.3 activity was significantly higher 
(p<0.01) with added aCD28 at every CsA concentration tested above 10 nM (Fig. 3.1D). 
Addition of aCD28 alone had no affect on Kv1.3 activity. Examining other activation 
markers, CsA did not inhibit expression of CD26 or expansion of cell volume after 
stimulation with aCD28 plus aCD3 (Fig. 3.1B,C). Previous studies found that strong 
CD28 co-stimulation led to expression of cytokines including IL-2 in the presence of 
high concentrations of CsA, (18, 20) by activating pathways separate from calcineurin-
signaling (21). Interestingly, stimulation with aCD3 plus aCD28 of cells treated with 100 
nM CsA led to significantly higher Kv1.3 activity than that found in cells stimulated 
without CsA (p<0.01, Fig. 3.1D). Expression of CD25 and CD26 also exhibited peak 
levels at 100 nM CsA. These results suggest that calcineurin-dependent signaling may 
negatively-regulate Kv1.3 activity and that the suppression of Kv1.3 activity by CsA after 
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stimulation with aCD3 alone was due to inhibition of molecules and pathways distinct 
from calcineurin. 
 
Figure 3.1  |  Effects of cyclosporin A (CsA) on Kv1.3 ion channel activity in CD4+ T cells 
after mitogenic stimulation. (A) Mean Kv1.3 activity ± standard error in CD4+ T cells (N = 20-
65 cells per point) isolated from PBMCs that were pre-incubated with the specified 
concentrations of CsA and stimulated for ~64 h with either anti-CD3 antibodies (□) or anti-CD28 
plus anti-CD3 antibodies (▲). (B) Flow cytometric analysis of mean CD26 expression in gated 
CD4+ T cells selected from PBMCs treated as described in (A). (C) Flow cytometric analysis of 
mean forward scatter (FSC) in gated CD4+ T cells. The solid grey lines in panels (A-C) represent 
values from T cells cultured for ~64 h without mitogenic stimulation and without CsA. (D) Box 
plots indicating the distributions of current through Kv1.3 ion channels in the CD4+ T cells 
described in (A). Large boxes depict the range of the 25th and 75th percentile of Kv1.3 currents, 
whiskers represent the 10th and 90th percentile of currents, and the median Kv1.3 current is 
depicted by the solid line, the mean Kv1.3 current by the black square (■) within the boxes. All 
measurements are from PBMCs isolated from the same human subject but were repeated and 
validated using a second subject. 
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3.4. Rapamycin inhibits the increase of Kv1.3 activity after mitogenic 
stimulation 
 While CsA affects IL-2 expression and the early stages of T cell activation, we 
used rapamycin to examine the role of late-stage events in the pathways leading to Kv1.3 
up-regulation. Rapamycin, another commonly used immunosuppressive drug, inhibits the 
mammalian target of rapamycin (mTOR) complex (22). The mTOR complex is a serine-
threonine kinase that regulates cellular growth and proliferation (23), generally after 
signaling of IL-2 through the IL-2 receptor (24). A major motivation for examining the 
effects of rapamycin on Kv1.3 activity was that we previously found that the increase in 
Kv1.3 activity correlated strongly with the increase in cell size after stimulation (7).   
 As shown in Figure 3.2, rapamycin inhibited, in a dose-dependent manner, the 
increase in Kv1.3 in CD4+ T cells after stimulation with aCD3 alone (IC50 = 5 nM). 
Examining the distributions of Kv1.3 currents in cells treated with high concentrations of 
rapamycin (100 nM and 1000 nM), the median and mean currents showed little 
difference from cells cultured without stimulation (p>0.2, Fig. 3.2D). At these 
concentrations of rapamycin, however, 10-15% of CD4+ T cells still exhibited high 
Kv1.3 activity (>0.6 nA), suggesting that Kv1.3 activity is not affected strongly by 
rapamycin in this subpopulation of cells. Comparing Kv1.3 activity to other activation 
markers, rapamycin inhibited proliferation, partially inhibited (~50%) expansion of cell 




Figure 3.2  |  Effects of rapamycin on Kv1.3 ion channel activity in CD4+ T cells after 
mitogenic stimulation. (A) Mean Kv1.3 activity ± standard error in CD4+ T cells (N = 23-53 
cells per point) isolated from PBMCs that were pre-incubated with the specified concentrations of 
rapamycin and stimulated for ~64 h with either anti-CD3 antibodies (□) or anti-CD28 plus anti-
CD3 antibodies (▲). (B) Flow cytometry analysis of mean CD26 expression in gated CD4+ T 
cells selected from PBMCs treated as described in (A). The solid grey lines in panels (A-C) 
represent values from T cells cultured without mitogenic stimulation and without rapamycin. (C) 
Flow cytometric analysis of mean forward scatter (FSC) in gated CD4+ T cells. (D) Box plots 
indicating the distributions of current through Kv1.3 ion channels in the CD4+ T cells described 
in (A). Measurements are from PBMCs isolated from the same human subject but were repeated 
and validated using a second subject.  
 
 
 Upon adding aCD28 to stimulation with aCD3, rapamycin still decreased Kv1.3 
activity in a dose-dependent manner. The addition of aCD28, however, led to ~50% 
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higher mean Kv1.3 activity at rapamycin concentrations between 1 and 1000 nM. Mean 
cell volume showed similar expansion upon stimulation with aCD3 and aCD28. These 
results suggest that while rapamycin inhibits the increase of Kv1.3 activity after 
stimulation, additional pathways can also increase Kv1.3 activity through mTOR-
independent pathways. 
 
3.5. Recombinant IL-2 increases Kv1.3 activity following stimulation of T 
cells 
 The addition of aCD28 to stimulation with aCD3 led to increased Kv1.3 activity 
in cells treated with either rapamycin or CsA. It was not clear, however, whether this 
increase was directly due to CD28 co-stimulatory pathways or to signaling induced by 
increased expression of cytokines such as IL-2. To answer this question, we measured the 
effects of high levels of recombinant IL-2 (rIL-2) on Kv1.3 activity in CD4+ T cells 
isolated from three separate human subjects. 
 In each of the four conditions tested (aCD3 with no drugs, aCD3 with 400 nM 
CsA, aCD3 with 100 nM rapamycin, and no aCD3 with no drugs), the addition of rIL-2 
led to a significant increase in Kv1.3 activity after ~64 h culture (p<0.01, Fig. 3.3). We 
observed the largest average Kv1.3 currents upon stimulation with rIL-2 and aCD3 in the 
presence of CsA, again suggesting a possible role of calcineurin-dependent pathways in 
negatively regulating Kv1.3 activity. In addition, even without added anti-CD3 
stimulation, rIL-2 increased mean Kv1.3 activity by a factor of ~2 compared to cells 
without added rIL-2. Distributions of Kv1.3 currents in cells stimulated with rIL-2 alone 
showed no significant differences compared to cells stimulated with aCD3 alone 
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(p=0.10). Previously, Lee et al. found that the mouse T lymphocyte line, L2, exhibited 
similar increases in Kv1.3 activity upon treatment with rIL-2 (25), although mice T cells 
exhibit marked differences in K+-channel behavior compared to human T cells (10, 26). 
Signaling through the TCR-CD3 complex, therefore, is not necessary for obtaining cells 
with high levels of Kv1.3 activity in human CD4+ T cells. 
 
Figure 3.3  |  Increase of Kv1.3 ion channel activity after culture with exogenous IL-2. (A) 
Mean Kv1.3 activity in CD4+ T cells isolated from PBMCs cultured for 60 hours with either anti-
CD3 antibodies (black bars), anti-CD28 plus anti-CD3 antibodies (striped bars), or recombinant 
IL-2 plus anti-CD3 antibodies (gray bars). Before stimulation, PBMCs were pre-incubated with 
either 400 nM CsA, 100 nM rapamycin, or no drugs, as indicated. All values represent the 
average and standard error of mean Kv1.3 measurements using three human subjects. (B) Box 
plots showing the distributions of current through Kv1.3 ion channels in the CD4+ T cells 
described in (A), with the grey boxes representing cells cultured with IL-2 and the white boxes 
representing cells without IL-2 and without anti-CD28 antibodies. Distributions were constructed 
by combining the individual Kv1.3 currents from all three human subjects (N = 47-128 cells per 
specified condition). Significant differences between distributions were determined using the 
Kolmogorov-Smirnov test and are depicted with ** (p < 0.01). 
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 We observed four additional interesting effects of rIL-2 on Kv1.3 activity. First, 
treating cells with rapamycin led to a significant decrease in Kv1.3 activity in cells 
stimulated with aCD3 and rIL-2 (p<0.01), again suggesting a partial role of mTOR 
pathways in regulating Kv1.3 activity. Second, flow cytometry studies of activation 
markers revealed that treating cells with rIL-2 in addition to aCD3 led to greatly 
increased CD25 and CD26 expression. In particular, the increased expression of CD25, 
which is part of the complex comprising the IL-2 receptor, especially may help explain 
increased Kv1.3 activity in cells treated with aCD3 and rIL-2 compared to cells treated 
with aCD3 alone. Treatment with rIL-2 in the absence of aCD3 stimulation did not lead 
to increased CD25 expression. Third, using quantitative RT-PCR, increased Kv1.3 
activity after stimulation did not correlate with increased expression of Kv1.3 mRNA 
(Fig. 3.4). And fourth, stimulating cells with aCD3 plus aCD28 plus rIL-2 showed no 
differences in Kv1.3 activity compared to cells stimulated with aCD3 plus rIL-2 (e.g. no 
aCD28), suggesting that aCD28 pathways do not have direct effects on Kv1.3 activity. 
Together, these results indicate that Kv1.3 activity is regulated by pathways induced by 
IL-2 induced signaling but not at the transcriptional level.  
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Figure 3.4  |  Quantitative RT-PCR measurements of KCNA (Kv1.3) and IL-2 mRNA 
expression after mitogenic stimulation. mRNA was extracted from CD4+ T cells isolated from 
PBMCs cultured for either 24 h (black bars) or 48 h (grey bars) with either anti-CD3 antibodies, 
anti-CD28 antibodies plus anti-CD3 antibodies, recombinant IL-2 plus anti-CD3 antibodies, or no 
added mitogenic antibodies,. RPLP0 was used as a normalizer gene, and expression levels of 
KCNA (left) and IL-2 (right) are expressed relative to the condition of no added mitogen 
stimulation (e.g. “no stim”). Values represent average ± standard deviation of triplicate 
quantitative RT-PCR measurements and are representative of two independent experiments from 
two human subjects. 
 
 
3.6. IL-15 and IL-2 increase Kv1.3 activity in the absence of CD3-signaling 
 While exogenous IL-2 increased Kv1.3 activity in CD4+ T cells, it was not clear 
through which mechanisms this increase might occur. The heterotrimeric receptor for IL-
2 (IL-2R) initiates downstream signaling through its IL-2Rβ and γc subunits, which 
activate Janus kinases (Jak)-1 and Jak-3 (27). These kinases in turn stimulate signaling 
transducers and activators of transcription (Stat)-3 and Stat5, as well as additional 
pathways (28). To ascertain which specific Jak/Stat pathways might be involved in 
regulating Kv1.3 activity, we measured the effects of the following recombinant human 
cytokines: IL-15, which activates Jak-1 and Jak-3 through its receptor which includes the 
IL-2Rβ and γc subunits (28); IL-6, which primarily activates Stat-1 and Stat-3 pathways 
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through Jak-1 and Jak-2 (29); and IL-10, which in T cells primarily activates Stat-3, as 




Figure 3.5  |  Effects of exogenous cytokines on Kv1.3 activity. Box plots represent 
distributions of currents through Kv1.3 ion channels in CD4+ T cells isolated from PBMCs 
cultured for ~64 h with either IL-2, IL-15, IL-6, IL-10, or no exogenous cytokines (N = 20-60 
cells per condition). Distributions on the left were from cells cultured only with the specified 
exogenous cytokine, while the distributions on the right were measured in cells cultured with 
anti-CD3 antibodies in addition to the indicated cytokine. Significant differences between 
specified distributions were determined using the Kolmogorov-Smirnov test and are depicted by * 
(p < 0.05) or ** (p < 0.01). 
 
 
 In the absence of stimulation with aCD3, both rIL-2 and recombinant IL-15 (rIL-
15) led to significantly increased Kv1.3 activity in CD4+ T cells compared to cells with 
no added cytokines (p<0.01, Fig. 3.5). Treating cells with recombinant IL-6 (rIL-6) or 
recombinant IL-10 (rIL-10) had no effect on Kv1.3 activity (Fig. 3.5). In cells stimulated 
with aCD3, only rIL-2 led to increased Kv1.3 activity compared to cells stimulated with 
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aCD3 but without cytokines (p<0.05). The cytokines rIL-6 and rIL-15 had no significant 
effects on Kv1.3 activity. The absence of an effect of rIL-15 on cells stimulated with 
aCD3 may be due to competition with expressed IL-2 for receptor activity (31). Finally, 
rIL-10 led to decreased Kv1.3 activity in cells stimulated with aCD3 compared to cells 
stimulated without cytokines (p<0.01), although this decrease may be due to decreased 
expression of IL-2 in cells treated with rIL-10 (32). Together these results highlight the 
importance of Jak-3 in regulating Kv1.3 activity through Stat-3 independent pathways. 
 
3.7. Tyrphostin AG-490 inhibits increase in Kv1.3 activity after stimulation 
 To confirm the role of Jak-3 in regulating Kv1.3 activity, we measured the effects 
of tyrphostin AG-490 on Kv1.3 activity in CD4+ T cells. Tyrphostin AG-490 is a potent 
inhibitor of Jak-2 and Jak-3 kinases (IC50 = ~25 μM) that inhibits proliferation of T cells 
(33, 34). Importantly, tyrphostin AG-490 does not affect Jak-1, Tyk-2, early activation 
kinases such as Lck and Syk, or expression of CD25 (34, 35).  
 As shown in Figure 3.6, treating cells with 100 μM tyrphostin AG-490 inhibited 
increases in Kv1.3 activity after stimulation. In all three stimulation conditions tested 
(aCD3 alone, aCD3 plus aCD28, and aCD3 plus rIL-2), Kv1.3 activity in cells treated 
with 100 μM tyrphostin AG-490 showed no significant differences compared to cells 
cultured without stimulation. Treating cells with a lower concentration of tyrphostin AG-
490 (10 μM) did not significantly reduce the increase of Kv1.3 activity upon stimulation 
(Fig. 3.6). This concentration was below the effective concentration for inhibiting Jak-3 
activity (34) but above the concentration reported for inhibiting Jak-2 (35). Tyrphostin 
AG-490 had no effects on upregulation of CD25 or CD26 except with stimulation by 
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aCD3 plus rIL-2, in which case expression was reduced to levels of aCD3 stimulation 
without rIL-2. These results, combined with the result that Jak-2 activation through IL-6 
had no effects on Kv1.3 activity, suggest that increases in Kv1.3 activity primarily occur 
through Jak-3-dependent pathways. 
 
Figure 3.6  |  Tyrphostin AG-490-induced inhibition of the increase of Kv1.3 activity after 
stimulation. (A) Box plots representing CD4+ T cells isolated from PBMCs cultured for ~64 h 
with either anti-CD3 antibodies, anti-CD28 plus anti-CD3 antibodies, or recombinant IL-2 plus 
anti-CD3 stimulation. Before stimulation, PBMCs were pre-incubated with either no tyrphostin 
(white boxes), 10 μM tyrphostin (striped boxes), or 100 μM tyrphostin (grey boxes). Significant 
differences between specified distributions were determined using the Kolmogorov-Smirnov test 
and are depicted by ** (p < 0.01). (B) Box plots representing flow cytometric distributions of 
CD25 expression in gated CD4+ lymphocytes selected from PBMCs described in (A), with white 
boxes depicting cells cultured with 0 μM tyrphostin and grey boxes depicting cells cultured with 
100 μM tyrphostin. (C) Box plots representing flow cytometric distributions of CD26 expression 
in gated CD4+ lymphocytes as described in (A). Measurements of Kv1.3 activity (N=19-45 cells 






 Potassium ion channels in T cells are emerging targets for the treatment of human 
autoimmune diseases (36, 37). Compounds that block Kv1.3 ion channel activity, in 
particular, are of interest because they potently suppress the effector memory phenotype 
of T cells (Tem) while having minimal effects on naïve or central memory phenotypes 
(38). The efficacy of blockers of Kv1.3 activity in animal models of MS, RA, and type 1 
diabetes presumably arises from this preferential suppression of Tem cells relevant to 
disease pathogenesis (8, 11, 13). While considerable efforts have focused on developing 
drug compounds to block Kv1.3 activity (15, 39, 40), the approach of altering Kv1.3 
activity by affecting its regulation has not been explored. In this study, we used high-
throughput profiling of Kv1.3 ion channels in CD4+ T cells to elucidate which pathways 
regulate Kv1.3 activity after stimulation. 
 The results presented here indicate that IL-2R pathways play a critical role in 
increasing Kv1.3 activity after stimulation of human T cells. Four findings support this 
conclusion: (i) rIL-2 and rIL-15, which both signal through the IL-2Rβ and γc subunits of 
the IL2-R, increased Kv1.3 activity in the absence of mitogenic stimulation (Fig. 3.5); (ii) 
adding rIL-2 to mitogenic stimulation increased Kv1.3 activity compared to mitogenic 
stimulation alone, presumably through increased levels of both IL-2 and IL-2R (Fig. 3.3); 
(iii) rapamycin, which inhibits cell cycle progression in T cells (41), suppressed Kv1.3 
activity after stimulation (Fig. 3.2); and (iv) CsA exhibited no inhibitory effects on Kv1.3 
activity when stimulation occurred in the presence of rIL-2 or aCD28, which can bypass 
CsA leading to expression of IL-2 (Fig. 3.1). Interestingly, calcineurin-dependent 
pathways activated by signaling through the TCR-CD3 complex may negatively regulate 
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Kv1.3 activity, as treating cells with CsA actually increased mean Kv1.3 activity after 
mitogenic stimulation in the presence of rIL-2 or aCD28 antibodies (Fig. 3.1). 
 In terms of which IL-2R pathways play roles in regulating Kv1.3 activity, we 
found that Jak-3-dependent pathways are critical for increasing Kv1.3 activity. Signaling 
through the IL-2Rβ and γc subunits of the IL-2R (by rIL-2 and rIL-15), which activate 
Jak-1 and Jak-3, led to increased Kv1.3 activity (Fig. 3.5). Signaling through Jak-1, Jak-
2, and Tyk-2 pathways (using rIL-6 or rIL-10) had no effects on Kv1.3 activity (Fig. 3.5). 
Lack of effects of rIL-6 also suggests that Stat3-activation does not regulate Kv1.3 
activity. Finally, tyrphostin AG-490, which selectively inhibits Jak-2 and Jak-3, 
suppressed the increase in Kv1.3 activity after mitogenic stimulation only at a 
concentration that completely inhibited Jak-3 (Fig. 3.6). 
 We found that mTOR-associated pathways regulate Kv1.3 activity, as rapamycin 
partially inhibited increase of Kv1.3 activity depending on stimulation conditions. The 
mTOR complex is a downstream target of Jak-3 (42), although it can also be activated by 
CD28-pathways through protein kinase B (Akt) signaling pathways (21, 43) or 
phosphatidylinositol-3-OH kinase (PI(3)K) pathways (44, 45). Two pieces of evidence 
suggest that CD28-activated pathways do not strongly regulate Kv1.3 activity. First, we 
observed only slight increases in Kv1.3 activity upon adding aCD28 to stimulation with 
aCD3 (Fig. 3.3). Second, tyrphostin AG-490 suppressed Kv1.3 activity in cells stimulated 
with aCD28 and aCD3 (Fig. 3.5), highlighting the importance of Jak-3 in regulating 
Kv1.3 activity even in presence of CD28-costimulation.  
 In addition to mTOR-pathways, other Jak-3 pathways independent of rapamycin 
contributed to regulation of Kv1.3 activity (Fig. 3.2). One such pathway likely to regulate 
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Kv1.3 activity is Stat-5, which can regulate rapamycin-independent cellular growth and 
survival through activation of Pim kinases (46). Other potential Jak-3 activated pathways 
that may play roles in regulating Kv1.3 activity are the Akt, PI(3)K, and mitogen-
activated protein kinases, although these pathways are not specific to Jak-3 activation 
(24). 
 Understanding the pathways involved in upregulating Kv1.3 activity in T cells has 
several implications for the roles and functions of Kv1.3 ion channels. First, as mentioned 
previously, T cells with high Kv1.3 activity have been found in inflammatory infiltrates 
from patients with MS (12). The fact that IL-2 and IL-15 can increase Kv1.3 activity 
independent of TCR-CD3 signaling (Fig. 3.6) suggests that these cells may acquire high 
Kv1.3 activity because of the cytokine environment in the infiltrates in addition to 
stimulation through the TCR. Second, the fact that T cell pathways associated with 
cellular growth also regulate Kv1.3 activity highlights the role of Kv1.3 ion channels in 
regulating T cell volume. Third, it is interesting that Kv1.3 ion channels are regulated by 
different mechanisms and pathways than the other major K+ channel in T cells, KCa3.1, 
which is regulated transcriptionally by protein kinase C (47). These differences may 
suggest molecular mechanisms by which different phenotypes of T cells acquire certain 
distributions of K+ ion channels, favoring either Kv1.3 or KCa3.1, after stimulation (8).  
 A major question regarding the regulation of Kv1.3 activity in T cells is the 
mechanism by which this regulation occurs. Previous reports have determined that the 
increased Kv1.3 activity correlates with increased number of active channels in the 
plasma membrane. We demonstrated, however, that increases in Kv1.3 activity did not 
correlate with increased expression of Kv1.3 mRNA (Fig. 3.4), a finding that agrees with 
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several previous studies (48, 49). The gene for Kv1.3 ion channels, interestingly, may 
even be an effective housekeeping gene in human T cells, as it demonstrated remarkable 
stability compared to GADPH and RPLP0 in quantitative RT-PCR studies. While not 
regulated at the transcriptional level, Kv1.3 activity may be increased through translation, 
through activation (50), or by insertion of pre-synthesized Kv1.3 channels into the plasma 
membrane from intracellular stores (4). The model of translational regulation seems 
promising given the role of mTOR and Stat-5 pathways in increasing translation which 
precedes cell growth and survival (51, 52). 
 A second question is whether affecting regulation of Kv1.3 ion channels may 
offer benefits similar to drug compounds that directly block Kv1.3 activity. The effects of 
rapamycin on Kv1.3 activity after stimulation are interesting given the potency of 
rapamycin as a clinical immunosuppressant. A recent study indicated that rapamycin 
altered lymphocyte trafficking by affecting down-regulation of chemokine receptor 7 
(CCR7) and CD62L in activated T cells (53). As activated Tem have low expression of 
CCR7 and CD62L, but elevated levels of Kv1.3 activity (8), it would be interesting if 
altered Kv1.3 activity in these cell types contributed to the effects of rapamycin.
 Finally, this study highlights the potential of using high-throughput methods of 
measuring Kv1.3 activity for performing immunological studies of T cell activation. The 
high-throughput method used here allowed automated and direct comparison of cells 
treated under different stimulation conditions or drug-treatments. In addition, the total 
number of CD4+ T cells measured for Kv1.3 activity in this study (>5000 cells) would be 
virtually impossible using traditional, manual techniques for measuring functional Kv1.3 
activity. Despite these enabling characteristics, current high-throughput 
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electrophysiology methods do have several drawbacks, including high cost, inability to 
measure ligand-gated ion channels, and lower throughput than true high-throughput 
methods such as flow cytometry; however, advances in microfluidics and 
microfabrication may address some of these limitations in the near future (54, 55). High-
throughput electrophysiology, therefore, offers a useful and accessible tool to study ion 
channel activity in T cells, and more importantly, as demonstrated in this study, may 
reveal insight into the functional roles of ion channels in immune responses and human 
disease.  
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Quantifying Disease Activity in Patients with Multiple Sclerosis and 
Rheumatoid Arthritis Based on Kv1.3 Ion Channel Activity in T Cells 
 
 This chapter examines using Kv1.3 activity in human T cells isolated from 
peripheral blood as a marker for the activity of autoimmune disease. We used a recently 
developed high-throughput assay to profile Kv1.3 activity in CD4+ and CD8+ T cells 
from patients with multiple sclerosis (MS) and rheumatoid arthritis (RA). Patients with a 
chronic progressive (CP) form of MS exhibited significantly higher Kv1.3 activity 
compared to healthy controls or MS patients in remission.  Developing metrics to 
quantify the percentage of T cells with “high” Kv1.3 activity made it possible to 
distinguish between CP-MS patients and controls with 100% sensitivity and 94% 
specificity. Controls with acute inflammatory disorders, however, also exhibited high 
Kv1.3 activity, suggesting that Kv1.3 activity is a general marker for active 
inflammation. We explored this hypothesis by examining a second autoimmune disease, 
RA.  Patients with an active form of RA exhibited significantly higher Kv1.3 activity 
than patients with inactive RA, and Kv1.3 activity correlated with erythrocyte 
sedimentation rate. High-throughput profiling of Kv1.3 ion channels in T cells introduces 
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a promising new strategy for quantifying activity of immune-mediated inflammation and 




 Kv1.3 ion channels in the plasma membrane of human T cells are emerging 
targets for the treatment of human autoimmune disease (1). Drug compounds that inhibit 
Kv1.3 selectively suppress activation of effector memory T (Tem) cells (2), which are 
implicated in the pathogenesis of several autoimmune diseases (3, 4). The Kv1.3 ion 
channel may also serve as a marker of autoimmune disease, as T cells increase the 
number of functional Kv1.3 ion channels in their plasma membrane after activation (5-7). 
Tem cells, including autoreactive T cells from peripheral blood of patients with MS and 
the synovial fluid of RA patients, experience an especially large increase (~5-fold) upon 
stimulation (7, 8). A recent report found these T cells with high Kv1.3 activity in 
inflammatory infiltrates in the brains of post-mortem MS patients, highlighting the 
importance of cells with high Kv1.3 activity for the pathogenesis of human disease (9).  
 While many previous studies have examined changes in various surface- and 
activation-markers in T cells from peripheral blood in the context of autoimmune disease 
(10-12), Kv1.3 ion channels have not been profiled in T cells from peripheral blood. A 
major reason may be that traditional techniques to quantify Kv1.3 channels (e.g. patch-
clamping) are low-throughput, labor-intensive, and not amenable to profiling Kv1.3 
activity in heterogeneous cell populations such as peripheral blood T cells (13). Recently, 
we developed a high-throughput method for measuring Kv1.3 activity in T cells (14). 
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This assay is automated, specific, and able to measure Kv1.3 activity in ~150 T cells 
within 1 h (14). Here, we use this assay to profile Kv1.3 activity in T cells isolated from 
the peripheral blood of patients with MS and patients with RA.  The results presented in 
this work indicate that MS and RA patients with active disease have elevated Kv1.3 
activity in their T cells compared to healthy controls or patients with inactive disease. 
Such quantitative measurements of disease activity may have clinical use for diagnosing 
and therapeutic monitoring of human autoimmune disease. 
 
4.2. Materials and Methods 
 We obtained peripheral, venous blood from control subjects and patients with MS 
or RA (Table 1 and Supporting Table 4-App.1). Patient history and a neurological exam 
allowed determination of whether MS patients had relapsing-remitting (RR-) or chronic 
progressive (CP-, either secondary-progressive, or primary-progressive) forms of MS. 
Similarly, RA patients were classified as having “active” (moderate-to-severe symptoms) 
or “inactive” (minimal or no symptoms) disease based on findings during a 
rheumatologic exam including number of inflamed joints and the necessity for changes in 
treatment regimen. All subjects provided written informed consent, and protocols were 
approved by the Institutional Review Board at the University of Michigan.  
 From freshly isolated blood from each patient, we isolated CD4+ and CD8+ T 
cells from PBMCs using commercially available magnetic bead separation techniques 
(Miltenyi Biotech, Auburn, CA). In these isolated T cells (examining CD4+ and CD8+ T 
cells for each patient in parallel), we measured electrical currents through Kv1.3 ion 
channels using a high-throughput electrophysiology device (IonWorks HT, MS 
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Analytical Technologies, Sunnyvale, CA) with protocols described elsewhere (14). 
Measurements of Kv1.3 activity occurred 3.9 ± 0.7 h (mean ± standard deviation) after 
the blood draw, with the exact same protocols (and similar time-lapses) used for all 
patients. 
 









Progressive (N=6) a 
Age (yr) 42.1 ± 11.2 43.0 ± 11.0 38.9 ± 9.1 53.5 ± 8.0 * 
Female gender (%) 60 71 80 50 
Ethnicity (%)     
Caucasian (%) 94 90 87 100 
African American (%) 6 10 13 0 
CBC values     
RBC (× 106 / mm3) 4.6 ± 0.5 4.6 ± 0.4 4.5 ± 0.4 4.6 ± 0.5 
WBC (× 103 / mm3) 6.3 ± 1.5 6.7 ± 1.9 6.3 ± 1.7 7.6 ± 2.2 
Lymphocytes (%) 30.5 ± 9.8 26.5 ± 6.7 27.2 ± 5.1 24.9 ± 9.7 
Flow cytometry measurements b    
CD4:CD8 ratio 1.7 ± 1.3 1.5 ± 1.3 1.1 ± 0.8 1.9 ± 1.7 
CD4+ Tem (%) c 11.1 ± 3.5 14.6 ± 3.9 * 14.5 ± 3.3 14.8 ± 5.0 
CD8+ Tem (%) c 17.7 ± 7.1 21.3 ± 4.6 21.0 ± 5.5 21.6 ± 4.0 
Kv1.3 measurements, number of cells measured per sample from each patient  
CD4+ T cells (N) 80 ± 16 71.7 ± 20.3 71 ± 21 75 ± 19 
CD8+ T cells (N) 62 ± 16 56.8 ± 19.1 56 ± 19 59 ± 21 
Values are expressed as mean ± standard deviation.  Significant differences between the indicated population 
and healthy controls are indicated by * (p<0.05). 
a Clinically diagnosed primary (N=3) or secondary progressive (N=3) MS 
b Flow cytometry performed using randomly-selected subsets of overall population, with 6 relapsing-remitting 
MS patients, 5 secondary/primary progressive MS patients, and 12 control subjects 
c Percentage of CD4+ or CD8+ T cells gated as CD62L- CD45RA- using custom-defined regions for each 




 To obtain additional information about patient blood samples, we carried out 
complete blood counts (CBCs, University of Michigan Clinical Laboratory) from whole 
blood; for RA patients, we additionally determined levels of C reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR). We also performed flow cytometric analysis using 
PBMCs and isolated CD4+ and CD8+ T cells (stored at 4° C prior to cytometry). Flow 
cytometry (FACScalibur, Becton Dickinson, Franklin Lakes, NJ) confirmed purity of 
isolated T cells (>95% for both CD4+ and CD8+ T cells), allowed determination of 
effector and memory subsets (using anti-CD62L-FITC and anti-CD45RA-APC), and 
provided quantification of activation markers (using anti-CD45RO-PE, anti-CD25-PE, 
and anti-CD26-PE, all antibodies monoclonal were anti-human antibodies from mouse, 
purchased from BD Biosciences, San Jose, CA). 
 To determine significant differences between patient populations, we used the 
non-parametric Mann-Whitney U test, and indicated the resulting p values throughout the 
text. For determination of correlation between variables, we used Pearson’s correlation 
coefficient (r) and computed statistical significance of the correlation using Student’s 
two-tailed t test (with p<0.05 indicating significant correlation). 
 
4.3. Results and discussion 
 We used a high-throughput assay to quantify Kv1.3 activity in T cells from 
peripheral blood of patients with MS (N=21) and healthy controls (N=17) (14). This 
assay afforded measurements of Kv1.3 activity in ~75 CD4+ T cells and ~60 CD8+ T 
cells per MS patient or control subject. For analysis, we classified MS patients (none of 
whom were on active treatment) as either relapsing-remitting (RR) or chronic-progressive 
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(CP) MS patients (Table 4.1). Importantly, none of the RR-MS patients had experienced 
active MS attacks in the 2 months prior to measuring Kv1.3 activity. 
 Patients with CP-MS exhibited significantly higher mean values of Kv1.3 activity 
in both CD4+ (25% higher, p=0.004) and CD8+ (40%, p=0.04) T cells compared to 
healthy controls (Fig. 4.1A). These differences were not due to the increased ages of CP-
MS patients compared to healthy controls; comparing Kv1.3 activity in CP-MS patients 
to a subset of healthy controls with ages that matched CP-MS patients (N=10 controls) 
again yielded significantly higher Kv1.3 in both CD4+ (20% higher p=0.03) and CD8+ 
subsets (37% higher, p=0.04) from CP-MS patients. In contrast to CP-MS patients, Kv1.3 
levels from patients with RR-MS displayed no differences compared to healthy controls 
in either CD4+ or CD8+ T cells. 
 While mean values afforded significant differences between CP-MS patients and 
healthy controls, this analysis did not utilize a major advantage of the high-throughput 
assay used in this work which results from obtaining distributions of Kv1.3 activity in 
individual T cells. In order to benefit from the information in these distributions of Kv1.3 
activity, we employed a technique commonly used in flow cytometry, quantifying the 
percentage of cells in a distribution with values above a defined threshold (Fig. 4.1B). To 
define this threshold, we constructed cumulative fraction plots to determine at which 
current values the distributions of Kv1.3 activity in CD4+ T cells from healthy controls 
and from CP-MS patients exhibited differences (Fig. 4-App.1). Interestingly, 
distributions of Kv1.3 activity from patients with CP-MS exhibited a general “shift” 
towards higher current values compared to distributions from healthy controls. The 
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current value that provided the maximal difference between current distributions from 
CP-MS patients and healthy controls was 0.32 nA (Fig. 4-App.1). 
 Using this optimized threshold, we analyzed the percentage of T cells from each 
healthy control and MS patient with “high” Kv1.3 activity above this threshold value 
(Fig. 4.1B,C). In CD4+ T cells, CP-MS patients exhibited a 2-fold higher average 
percentage of T cells with high Kv1.3 activity compared to controls (p<0.0001). In 
addition, this metric made it possible to distinguish between CP-MS patients and healthy 
controls with 100% sensitivity and 94% selectivity (Fig. 4.1C and Fig. 4-App.2). In CD8+ 
T cells, CP-MS patients also exhibited a significantly higher (~2-fold, p=0.03) percentage 
of T cells with high Kv1.3 activity compared to healthy controls, although individual 
values overlapped between the two populations (Fig. 4.1D). Similarly to the analysis of 
mean values of Kv1.3 activity, these differences were not due to age differences between 
CP-MS patients and healthy controls (Fig. 4.1C). Also, as in the case with mean values, 
patients with RR-MS did not exhibit differences in either CD4+ or CD8+ T cells using 
threshold metrics. These results indicate that CP-MS patients, with active symptoms of 
MS, have an increased percentage of T cells (especially in the CD4+ subset) in peripheral 
blood with high Kv1.3 activity compared to healthy controls or patients in a relapsing 





Figure 4.1 |  Kv1.3 ion channel activity in T cells isolated from peripheral blood of patients 
with MS or RA compared to activity from controls. (A) Mean Kv1.3 activity in T cells from 
healthy controls (HC), relapsing-remitting MS patients (RR-MS), and chronic-progressive MS 
(CP-MS) patients. (B) Representative histograms of Kv1.3 activity in CD4+ T cells from a 
healthy control (top) and from a patient with CP-MS (bottom). The dashed line indicates the 
threshold for classifying T cells as having “high” levels of Kv1.3 activity. (C) Percentage of 
CD4+ T cells with high Kv1.3 activity for each HC, RR-MS, and CP-MS patient studied. Square 
symbols represent patients or controls between the ages of 40 and 65. (D) Percentage of CD8+ T 
cells with high Kv1.3 activity for each control subject or MS patient. (E) Average percentage of T 
cells with high Kv1.3 activity from RA patients with active (RA-ACT) and inactive (RA-INACT) 
disease. (F) Percentage of CD8+ T cells with high Kv1.3 activity as a function of either 
erythrocyte sedimentation rate (ESR, left) or levels of C reactive protein levels (CRP), measured 
from patients with active (gray triangles) and inactive (black squares) RA. Columns with error 
bars depict average ± standard deviation. Significant differences between specified control and 
MS populations were determined using the Mann-Whitney U test. Resulting p values are 
indicated above the columns that are compared. 
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 In addition to healthy controls, we also measured Kv1.3 activity in T cells from 
three “diseased” controls displaying active symptoms of an inflammatory disorder 
(diverticulitis, urinary tract infection (UTI), or recent myocardial infarction combined 
with type 2 diabetes) at the time of blood draw (Fig. 4-App.4). The CD4+ subset of T 
cells from all three subjects contained a significant percentage of cells with high Kv1.3 
activity, similar to patients with CP-MS (Fig. 4-App.4). Subjects with active IBD or UTI 
exhibited an especially high percentage of CD4+ T cells with high Kv1.3 (~35%). These 
results suggest that high Kv1.3 in T cells as a marker of disease is not specific to patients 
with MS, but may be indicative of general inflammatory disorders. 
 To test this hypothesis, we measured Kv1.3 activity in T cells from peripheral 
blood of patients with a second autoimmune disease, RA (N=10). All of the RA patients 
were on active therapy, but only half of the patients exhibited “active” symptoms of RA 
(moderate-to-severe) at the time of blood draw (4-App.Table). Using the same threshold 
metrics defined for MS patients, we found that patients with active RA had a significantly 
higher average percentage (80% higher) of cells with high Kv1.3 activity in CD8+ T cells 
compared to patients with inactive RA (p=0.03) or healthy controls (p=0.04) (Fig. 4.1E). 
Interestingly, we found no significant differences in Kv1.3 activity in CD4+ T cells from 
patients with active RA compared to patients with inactive RA (Fig. 4.1E). 
 Comparing Kv1.3 activity in each RA patient to CRP and ESR values, which are 
commonly used clinical markers for inflammation, we found that the percentage of CD8+ 
T cells with high Kv1.3 activity correlated significantly with ESR (p<0.05, Fig. 4.1F). 
Interestingly, ESR values themselves were not significantly different (p=0.20) in the 
active and inactive RA populations examined. Kv1.3 activity in CD4+ T cells did not 
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correlate with ESR, and CRP did not correlate with Kv1.3 activity in either CD4+ or 
CD8+ T cells (Fig. 4.1F). These results suggest that Kv1.3 activity in CD8+ T cells of RA 
patients is a marker of immune-mediated inflammation that correlates more strongly with 
disease activity than do general inflammation markers such as CRP and ESR. 
 A major question that arises from this work is what factors lead to increased 
Kv1.3 activity in T cells in peripheral blood in vivo. To address this question, we 
performed flow cytometric analyses of activation and differentiation markers from 
patients with CP-MS and healthy controls to correlate with Kv1.3 activity.  The 
percentages of CD4+ T cells that were central memory (Tcm) or naïve (Tnaive) exhibited no 
correlations to Kv1.3 activity (Fig. 4-App.6). Interestingly, the percentages of CD4+ T 
cells that were of the effector memory (Tem) phenotype did correlate weakly (p=0.08) to 
Kv1.3 activity, although this correlation was negative. This finding is surprising given 
that Tem cells strongly upregulate Kv1.3 activity upon activation (7).  
 Examining mean fluorescence intensity (MFI) of known activation markers in the 
entire population of CD4+ T cells, we found that neither CD25, CD26, nor CD45RO 
exhibited significant differences between CP-MS patients and healthy control subjects, in 
contrast to mean Kv1.3 activity (Fig. 4.1, Fig. 4-App.7). Interestingly, mean Kv1.3 
activity did correlate significantly to CD26 expression specifically in the Tnaive subset 
(p<0.04), examining individual patients or subjects (there were no other significant 
correlations). This correlation is interesting because elevated expression of CD26 in 
peripheral blood T cells has been reported for RR-MS patients with active clinical 
symptoms (11, 15). Kv1.3 activity and CD26 expression, therefore, may exhibit similar 
levels that are altered to similar extents in patients with different forms of MS; Kv1.3 
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activity, however, is a superior marker (also compared to CD25 or CD45RO) for 
distinguishing between CP-MS patients and healthy control subjects. 
 The flow cytometry analysis of T cell activation markers did highlight one major 
advantage of using Kv1.3 activity as a marker of T cell activation. Expression of CD25, 
CD26, and CD45RO depended heavily on whether the T cell was of the Tem, Tcm, or Tnaive 
phenotype. In general, memory T cells (either Tcm or Tem) exhibited greater than 2-fold 
expression of activation markers compared to Tnaive cells (Fig. 4-App.7). As a result, 
changes in MFI in the total CD4+ population of these activation markers may be a result 
of either activation of cells or altered percentages of Tnaive or memory cells. Kv1.3 
activity, in contrast, exhibited 2 to 5-fold lower coefficients of variations than these 
activation markers, indicating significantly decreased differences in activity among 
various phenotypes of T cells. This low variation makes Kv1.3 activity a sensitive marker 
for detecting differences in T cells from peripheral blood between various populations of 
human subjects or patients. 
 Several other factors lead to elevated Kv1.3 activity in T cells. Inflammatory 
cytokines, such as interleukin (IL)-2 and IL-15, can increase Kv1.3 activity in T cells, 
even in the absence of antigenic stimulation (6, 16). Another recent study found that a 
decreased glutamate level (which is associated with several autoimmune disorders) 
increased functional activity of Kv1.3 ion channels in T cells (17). In addition, T cell 
activation can also lead to increased Kv1.3 activity in T cells (14, 18). High Kv1.3 
activity in T cells, therefore, may represent the integrated effect of three stimuli: (i) 
inflammatory serum conditions; (ii) cytokines; and (iii) T cell stimulation.   
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 There are several potential clinical applications of measuring Kv1.3 activity in 
peripheral blood T cells. One promising use is for aid in diagnosing patients with 
primary-progressive MS, as Kv1.3 activity in CD4+ T cells afforded a 97% accuracy in 
distinguishing between CP-MS and healthy controls (Fig. 4.1C and Fig. 4-App.2). 
Another application of Kv1.3 activity may be to determine progression of patients with 
RR-MS to CP-MS, which is especially important given the fact that CP-MS patients are 
generally resistant to traditional MS therapies (19, 20). As a third clinical application, 
Kv1.3 activity in CD8+ T cells may also be useful as a marker of therapeutic monitoring 
of inflammation in patients with RA. High-throughput electrophysiology to measure 
Kv1.3 activity in T cells, therefore, offers a promising new strategy to quantify activity of 
immune-mediated inflammation for diagnosing and therapeutic monitoring of human 
autoimmune disease.    
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Chapter 4 Appendix 
 
4-App.Table. Characteristics of RA patients at the time of blood draw 
Patient ID Age (yr) 
Gender 









Patients with active RA    
1 55 F azathioprine, prednisone, infliximab 15 44 
2 59 F sulfasalazine, prednisone, hydroxychloroquine 22 34 
3 53 F adalimumab 25 25 
4 41 F prednisone, hydroxychloroquine 4 19 
5 53 F methotrexate, sulfasalazine, prednisone, rituximab 20 19 
Avg ± 
Stdev 52 ± 7   17 ± 8 28 ± 11 
      
Patients with inactive RA    
6 36 F methotrexate 16 21 
7 46 F leflunomide, prednisone, hydroxychloroquine 19 17 











10 69 F hydroxychloroquine 20 12 
Avg ± 
Stdev 51 ± 13   14 ± 7 16 ± 3 
All patients were Caucasian. 
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Figure 4-App.1  |  Optimizing thresholds for determining T cells with high Kv1.3 activity.  
(A) Cumulative fraction plot depicting percentage of CD4+ T cells from chronic progressive MS 
patients (CP-MS, −) and healthy controls (HC, −) with Kv1.3 currents greater than the threshold 
current value indicated by the x-axis.  Plots indicate the combined Kv1.3 currents from 6 CP-MS 
patients (448 cells total) and 17 HC-MS patients (1427 cells total).  (B) Cumulative fraction plots 
as described in (A) with relapsing-remitting MS patients (RR-MS, −, 1058 cells total) instead of 
CP-MS patients.  (C) Difference, D, between cumulative fractions of CP-MS patients and HC 
subjects as a function of current threshold.  The optimal threshold was defined as the largest 
current value that provided a D>13%.  (D) Difference, D, between cumulative fraction plots of 
RR-MS paitents and HC subjects. 
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4-App.2. Receiver operating characteristic (ROC) curve depicting 
sensitivity versus (1-sensitivity) for determining between chronic 
progressive MS patients and healthy controls 
 
 
Figure 4-App.2  |  Receiver operating characteristic (ROC) curve depicting sensitivity 
versus (1-specificity) for determining between chronic progressive MS patients (CP-MS) 
and healthy controls. ROC curves represent a useful statistical tool to evaluate diagnostic 
tests. For a list of all possible “threshold” values to separate two patient populations (here 
examining the percentage of CD4+ T cells with high Kv1.3 activity in CP-MS patients 
and control subjects), sensitivity and specificity are calculated. Sensitivity is then plotted 
as a function of (1-specificity), and the resulting area under the curve is known as the 
“ROC” value. An ROC value of 100% represents a diagnostic test that affords 100% 
sensitivity and 100% specificity. In the figure above, examining the percentage of CD4+ 
T cells with high Kv1.3 activity afforded an ROC of 99%, indicating that the metric is 
effective at determining between CP-MS patients and healthy controls. 
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Figure 4-App.3  |  Correlation between Kv1.3 activity and age in healthy control subjects 
and chronic progressive MS patients.  (A) Percentage of CD4+ T cells with high Kv1.3 activity 
as a function of age, with each point representing values from a single healthy control (■) or 
chronic progressive MS patient (▲).  Solid lines represent linear best fits to the data, with the red 
line fitting data from chronic progressive MS patients, and the black line fitting data from healthy 
controls.  Parameters detailing the quality of the fit are in the table below the panel. (B) 
Percentage of CD8+ T cells with high Kv1.3 activity as a function of age, with the same 
conditions as panel (A) except with CD8+ T cells. Correlations were computed using Pearson’s 
correlation coefficient (r) with significance of the correlation computed using Student’s t test 
(p<0.05 indicates significance).   
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4-App.4. Kv1.3 activity in CD4+ T cells from control subjects exhibiting 
active symptoms of disease at time of blood draw 
 
 
Figure 4-App.4  |  Kv1.3 activity in CD4+ T cells from control subjects exhibiting active 
disease at the time of blood draw.  (A) Histogram of Kv1.3 activity in CD4+ T cells from an 
individual chronic progressive MS patient (N=106 cells). This histogram serves as a reference for 
histograms from diseased controls. The percentage listed above the histogram represents the 
percentage of CD4+ T cells with high Kv1.3 activity above the threshold used throughout this 
work. (B) Histogram of Kv1.3 activity in CD4+ T cells from a control subject with type 2 diabetes 
and a recent myocardial infarction (N= 94 cells). (C) Same as panel (B) for a control subject with 
acute diverticulitis (N=99 cells). (D) Same as panels (A,B) for a control subject with a urinary 
tract infection (N=80 cells). 
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4-App.5. Correlation between Kv1.3 activity and subsets of CD4+ T cells 
 
Figure 4-App.5  |  Correlation between Kv1.3 activity and percentage of effector and 
memory subsets in CD4+ T cells.  (A) Representative flow cytometric plot of markers (CD62L 
and CD45RA) used to define effector memory (Tem), central memory (Tcm), and naïve (Tnaive) 
subsets within CD4+ T cells.  Note that “gating” regions were adjusted for each subject or patient, 
using density plots to define boundaries between subsets. (B) Average percentage of CD4+ T cells 
that were Tem, Tcm, or Tnaive, respectively, from healthy controls and chronic progressive MS 
patients.  Columns represent average ± standard deviation, with p values determined using the 
Mann-Whitney U test. (C) Percentage of CD4+ T cells with high Kv1.3 activity plotted as a 
function of the percentage of CD4+ T cells that were Tem for each individual healthy control (■) or 
chronic progressive MS patient (▲).   Solid lines represent linear fits to the data, with the red line 
fitting data from chronic progressive MS patients, and the black line fitting data from healthy 
controls.  Parameters detailing the quality of the fit are in the table below the panel. (D) Same as 
panel (C) examining Tcm cells instead of Tem cells.  (E) Same as panels (C,D) examining Tnaive 
cells instead of Tem or Tcm cells. Correlations were computed using Pearson’s correlation 
coefficient (r) with significance of the correlation computed using Student’s t test (p<0.05 
indicates significance).   
 124
4-App.6. Correlation between Kv1.3 activity and subsets of CD8+ T cells 
 
 
Figure 4-App.6  |  Correlation between Kv1.3 activity and percentage of effector and 
memory subsets in CD8+ T cells.  (A) Sample flow cytometric plot of markers (CD62L and 
CD45RA) used to define effector memory (Tem), central memory (Tcm), naïve (Tnaive), and Temra 
subsets within CD8+ T cells.  Note that “gating” regions were adjusted for each subject or patient, 
using density plots to define boundaries between subsets. (B) Average percentage of CD8+ T cells 
that were Tem, Tcm, Tnaive, or Temra respectively, from healthy controls and chronic progressive MS 
patients.  Columns represent average ± standard deviation, with significant differences between 
MS and control populations determined using the Mann-Whitney U test. (C) Percentage of CD8+ 
T cells with high Kv1.3 activity plotted as a function of the percentage of CD8+ T cells that were 
Tem for each individual healthy control (■) or chronic progressive MS patient (▲).   Solid lines 
represent linear fits to the data, with the red line fitting data from chronic progressive MS 
patients, and the black line fitting data from healthy controls.  Parameters detailing the quality of 
the fit are in the table below the panel. (D) Same as panel (C) examining Temra cells instead of Tem 
cells.  (E) Same as panels (C,D) examining Tcm cells instead of Tem or Temra cells.  (F) Same as 
panels (C,D,E) examining Tnaive cells instead of Tem,Tcm, or Temra cells. Correlations were 
computed using Pearson’s correlation coefficient (r) with significance of the correlation 
computed using Student’s t test (p<0.05 indicates significance).   
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4-App.7. Comparison of Kv1.3 activity to other T cell activation markers in 
CD4+ T cells from peripheral blood of patients with chronic progressive MS 





Figure 4-App.7  |  Comparison of Kv1.3 activity to other T cell activation markers in CD4+ 
T cells from peripheral blood of patients with chronic progressive MS or healthy controls.  
(A) Mean Kv1.3 activity in CD4+ T cells, with columns depicting average ± standard deviation 
from healthy controls (N=12) or patients with chronic progressive MS (N=5).  (B) Mean 
fluorescence intensity (MFI) of anti-CD25-PE in all CD4+ T cells (total) or in effector memory 
(Tem), central memory (Tcm), or naïve (Tnaive) subsets as defined in Figure 4-App.5.  (C) MFI of 
anti-CD26-PE in all CD4+ T cells (total) or in Tem, Tcm, or Tnaive subsets.  (D) MFI of anti-
CD45RO-PE in all CD4+ T cells (total) or in Tem, Tcm, or Tnaive subsets.  Differences between MS 
patients and control subjects were determined using the Mann-Whitney U test, with significance 
indicated as *** (p<0.01), ** (p<0.05), or * (p<0.10). 
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4-App.8. Comparison of Kv1.3 activity to other T cell activation markers in 
CD8+ T cells from peripheral blood of patients with chronic progressive MS 





Figure 4-App.8  |  Comparison of Kv1.3 activity to other T cell activation markers in CD8+ 
T cells from peripheral blood of patients with chronic progressive MS or healthy controls.  
(A) Mean Kv1.3 activity in CD8+ T cells, with columns depicting average ± standard deviation 
from healthy controls (N=12) or patients with chronic progressive MS (N=5).  (B) Mean 
fluorescence intensity (MFI) of anti-CD25-PE in all CD8+ T cells (total) or in effector memory 
(Tem), central memory (Tcm), naïve (Tnaive), or Temra subsets as defined in Figure 4-App.6.  (C) 
MFI of anti-CD26-PE in all CD8+ T cells (total) or in Tem, Tcm, Tnaive, or Temra subsets.  (D) MFI of 
anti-CD45RO-PE in all CD8+ T cells (total) or in Tem, Tcm, Tnaive, or Temra subsets.  Differences 
between MS patients and control subjects were determined using the Mann-Whitney U test, with 
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Conclusions and Future Applications 
 
5.1. Evaluation and potential impact of high-throughput screening of ion 
channels for clinical and immunological applications 
 In this thesis, we developed a high-throughput assay for measuring ion channel 
activity in human T cells, and we applied this assay to address relevant clinical and 
immunological questions. There are several areas in which this work may have impact. 
 The assay developed in this work is the first application of high-throughput 
electrophysiology to a primary cell type. While we focused on measuring Kv1.3 currents 
in different subsets of lymphocytes, the methodology may be general to a range of 
primary cell types and ion channel species. Compared to traditional patch clamping, high-
throughput devices offer several advantages including high-degree of automation, a more 
than 20-fold higher throughput, and the ability to compare cells in parallel under well-
defined conditions. In addition, the high-throughput approach afforded distributions of 
ion channel activity in single cells, which is important for analyzing heterogeneous 
populations of cells such as lymphocytes. The advantages afforded by this assay make the 
study of ion channels in primary cells accessible to a host of immunologists and 
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clinicians who currently lack the expertise, equipment, and initiative to perform manual 
patch clamp.   
 In terms of clinical applications, this work provides a new approach to 
quantifying activity of human autoimmune diseases. Measuring Kv1.3 activity afforded 
97% accuracy in distinguishing between healthy controls and patients with chronic 
progressive MS, and thus offers a promising approach for diagnosing primary progressive 
MS. Currently, diagnosing primary progressive MS can present significant clinical 
challenges; one of the patients examined in this study exhibited unexplained MS-like 
symptoms for 18 years before clinical diagnosis of primary-progressive MS. This patient 
displayed a large percentage of CD4+ T cells with high Kv1.3 activity. Measuring Kv1.3 
activity may make it possible to diagnose MS at an early stage in such difficult cases.  
 Another potential clinical application of measuring Kv1.3 activity is to determine 
progression of relapsing-remitting MS to chronic progressive MS. Patients who progress 
to chronic progressive MS become resistant to several treatments that are beneficial for 
relapsing-remitting MS patients (1, 2). Measuring Kv1.3 activity may allow for 
optimizing effective therapeutic options for these progressive patients. A third potential 
clinical application of Kv1.3 activity, i.e. therapeutic monitoring of patients with RA, is 
discussed in detail later in this chapter as a promising future application of this work. 
 In terms of immunological implications, this work provides new insights into the 
changes in Kv1.3 activity in T cells upon activation. The high-throughput assay for 
measuring Kv1.3 activity enabled detailed time-courses of Kv1.3 activity upon 
stimulation, as well as the ability to profile the varied and heterogeneous responses of 
control subjects in upregulation of Kv1.3 activity after stimulation. We also explored T 
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cell pathways that regulate Kv1.3 activity. Many of these immunological experiments 
would be impractical or impossible using traditional patch clamp techniques. In addition, 
understanding the regulation of Kv1.3 activity offers insight into novel therapeutic 
approaches to disrupt Kv1.3 ion channel activity for altering Ca2+-signaling, migration, or 
proliferation of T cells. Such approaches may be useful in treatment of autoimmune 
diseases, similar to approaches currently being explored using drug compounds to block 
Kv1.3 activity. 
 Despite the advantages and potential clinical applications of the high-throughput 
assay presented in this work, there are several drawbacks that may limit the use of Kv1.3 
activity in clinical settings. First, high-throughput electrophysiology devices are typically 
very expensive and only found in pharmaceutical companies. Even after acquiring the 
instrument, individual experiments remain expensive (due to the costs of the disposable 
patch plate substrate) compared to standard clinical tests. Second, these electrophysiology 
devices are not currently produced for clinical applications, and variations in different 
devices, patch plates, and protocols may not allow elucidation of the differences in Kv1.3 
activity between patient populations (especially when compared between different 
clinical facilities). And third, while we demonstrated significant differences in Kv1.3 
activity between patient populations, studies with a larger numbers of patients will be 
needed to establish Kv1.3 activity as a quantitative measurement that affords clinically 
relevant and practical advantages over currently used clinical markers and techniques. 
 Despite these challenges, high-throughput profiling of ion channels enables a 
range of clinical and immunological studies that would not be possible using traditional 
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patch clamp. The remainder of this chapter discusses some of the potential future 
applications of this promising technology. 
 
5.2. High-throughput screening of Kv1.3 ion channels for therapeutic 
monitoring of RA 
 The most promising future application of the work presented in this thesis is to 
use high throughput screening of ion channels in T cells to quantify disease activity for 
therapeutic monitoring in patients with RA. In our preliminary study of Kv1.3 ion 
channels in patients with RA, Kv1.3 activity in CD8+ T cells correlated with disease 
activity. This correlation was stronger than the correlation between disease activity and 
either erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) levels. These last 
two markers are commonly used by rheumatologists and are general for inflammation 
(3); these markers, however, are not specific to a certain cell type or inflammation 
mechanism. Therefore, Kv1.3 activity might provide an improved clinical measurement 
for quantifying disease activity, and in addition might determine which subset of 
lymphocytes is stimulated during this active disease. Another motivation for using RA as 
a model disease is the diverse different treatment options for RA, with several drugs 
exhibiting different mechanisms of action to suppress RA (4, 5). Knowing the activity of 
certain subsets of lymphocytes (assessed by Kv1.3 measurements) may provide 
additional clinical insight to aid the rheumatologist in selecting and monitoring a 
treatment regimen. A prospective study would be the following: 
• Recruitment of patients with RA who are on active treatment. A sample patient 
population might consist of patients on adalimumab (a TNF-α inhibitor), patients on 
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rituximab, which depletes B cells (6), patients on methotraxate (affects purine 
metabolism and inhibits T cell activation) and patients on prednisone (an orally 
delivered steroid). 
• At regular intervals (3 months), patients would donate ~10-20 mL of their peripheral 
blood for measurement of Kv1.3 activity in both CD4+ and CD8+ T cells. Patients 
would also provide blood in the case of an adverse event, such as a flare of symptoms 
associated with RA. It might also be interesting to quantify Kv1.3 activity in B cells; 
a recent report highlighted the role of memory B cells in relapses of RA patients 
treated with rituxan (7), and these B cells have been reported to exhibit high levels of 
Kv1.3 activity (8).  
• In addition to Kv1.3 measurements the following standard clinical measurements 
would be taken: complete blood count (CBC), ESR, CRP, number of inflamed joints, 
and a disease activity index for RA. 
• We would also measure serum levels of glutamate and selected cytokines using 
ELISA. Recently, Poulopoulou et al. found that patients with active systemic lupus 
erythematosus (SLE) had lower serum levels of glutamate than healthy controls or 
patients with inactive SLE (9). They also found that in vitro, low levels of glutamate 
led to increased Kv1.3 activity in T cells compared to control levels of glutamate. In 
addition, we found that exogenous cytokines increased Kv1.3 activity in the absence 
of TCR stimulation. Therefore, it would be clinically and scientifically interesting to 
correlate Kv1.3 activity to these serum markers in order to understand the 
physiological relevance of T cells with high Kv1.3 activity in peripheral blood. 
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The above tests would determine the extent to which Kv1.3 activity is a useful clinical 
marker of disease activity, and it would also provide general information about the 
correlation of serum glutamate levels and cytokines with Kv1.3 activity in the context of 
RA.  
 
5.3. High-throughput screening of Kv1.3 ion channels for diagnosis of MS 
 The original goal of the work presented in this thesis was to develop a new tool to 
aid in the diagnosis of MS. Despite advances in understanding the pathogenesis of MS, 
clinical diagnosis of MS remains a significant challenge (10). The criteria for diagnosis 
(MacDonald criteria) require clinical evidence of lesions in the brain (typically using 
MRI) disseminated in time and space (11). As a result, diagnosis typically occurs well 
after damage to the brain has already occurred, typically several years after presentation 
of initial symptoms (12, 13). An ideal clinical test would afford definitive diagnosis of 
MS at the first presentation of clinical symptoms. 
 In profiling of Kv1.3 activity in patients with MS, we found that patients with 
progressive forms of MS had significantly higher Kv1.3 activity in their CD4+ T cells 
compared to healthy controls. While measurements of Kv1.3 activity have potential 
clinical applications for diagnosing patients with primary progressive MS, patients with 
relapsing-remitting (RR-) MS (all of whom were in remission) did not exhibit differences 
in Kv1.3 activity compared to controls. To be able to distinguish between healthy 
controls and RR-MS patients, we attempted to detect differences in Kv1.3 activity in T 
cells from controls and RR-MS patients upon specific stimulation of PBMCs using MS-
relevant myelin antigens (14). These antigens consisted of myelin basic protein (MBP), 
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as well as selected peptides from MBP, proteolipid protein, and myelin oligodendrocyte 
glycoprotein (14). Stimulation protocols involved adding antigen to PBMCs at various 
concentrations, and testing either Kv1.3 activity or activation markers using flow 
cytometry at times after stimulation ranging from 3 d to 2 weeks. 
 Unfortunately, these stimulation protocols never resulted in differences between 
PBMCs stimulated with antigen and PBMCs cultured without stimulation. Within 2 
weeks, most naïve and central memory T cells died, leaving enriched populations of 
effector memory T (Tem) cells. These populations, however, were nearly identical (both 
before and after mitogenic stimulation) whether PBMCs were cultured with or without 
antigen, suggesting that disease-reactive T cells did not proliferate sufficiently to be 
detected above the background population of Tem cells (Fig. 5.1).  Interestingly, these T 
cells cultured for 7 d without stimulation exhibited very high levels of Kv1.3 activity 
upon stimulation, which is indicative of Tem cells.  
 In the works from the Chandy group in which disease-specific autoreactive T cell 
lines were generated from the blood of MS and control patients (Fig. 1.3), stimulation 
proceeded over the course of 6 weeks and usually involved multiple blood draws to 
replenish antigen presenting cells (15, 16). Such long stimulation times are needed for 
non-specific cells to die, leaving only proliferating disease reactive cells. These protocols 
are not conducive, however, to a diagnostic assay. Profiling of Kv1.3 activity after 
stimulation with MS-specific antigens, therefore, provides significant challenges for 





Figure 5.1  |  Kv1.3 activity in T cells upon antigen-specific stimulation. Using a healthy 
control subject, Kv1.3 activity was initially measured from CD4+ T cells isolated from freshly 
drawn blood (left). PBMCs from this control were then cultured either with 1× tetanus toxoid 
(green) or without added stimulation (black) for 7 d prior to Kv1.3 measurements in isolated 
CD4+ T cells (middle). After 7 d culture, PBMCs from these two conditions were suspended in 
fresh media and stimulated with anti-CD3 antibodies (aCD3) for 48 h prior to measurements of 
Kv1.3 activity in CD4+ T cells (right). There were no significant differences between cells with or 
without specific stimulation in any condition. These findings were also representative of specific 
stimulation of PBMCs from MS patients with myelin-specific antigens.   
 
 
 Despite the problems associated with antigen-specific stimulation, profiling Kv1.3 
activity from peripheral blood might still have applicability for diagnosing RR-MS. In 
particular, correlating neurological symptoms, an MRI-detected lesion, and high activity 
of T cells in peripheral blood (using Kv1.3 levels as a marker for T cell activity) at the 
presentation of first symptoms might provide a method to diagnose MS. The limitations 
of such experiments are difficulties in accessing such patient populations (before 
treatment with immunosuppressive drugs) and the long time scale (~3 years) needed to 





5.4. Technological enhancements to improve throughput of automated 
electrophysiology devices 
 In the experiments throughput this thesis, the IonWorks HT technology afforded 
measurements of Kv1.3 activity in 100-200 T cells per experimental run (~1 h). While 
this throughput is significantly higher than traditional manual patch-clamp, it is still 
several orders of magnitude lower than a true high-throughput technology (e.g. flow 
cytometry). Higher throughput would enable the quantification of Kv1.3 activity in 
additional lymphocyte subsets (or treatments with different immunosuppressive drugs) in 
parallel, and it would also provide a more accurate profiling of ion channel activity in cell 
types with heterogeneous expression of ion channels. We found that the throughput of the 
assay presented in this work depended strongly on subset (with B cells having less than a 
25% success rate for measurements) (Fig. 5.2). The reasons for the different throughputs 
of various subsets of lymphocytes are not clear but may provide insights into improving 
throughput of the IonWorks HT for experiments with primary lymphocytes (Fig. 5.2).  
 The first strategy for improving throughput is to modify the surface properties of 
the “patch plate” for performing planar patch-clamp using the IonWorks HT platform. 
Currently, the “patch plate” is composed of plastic (polyimide) which results in low seal 
resistances between the attached cell and substrate (compared to traditional patch clamp 
using glass substrates (18)). These low seal resistances lead to instability of the cell on 
the substrate, especially after application of drug (Fig. 5.2), as well as a large “leak” 
current that can mask small currents. Coating the patch plate with poly-L-lysine or with a 
thin-film of a glass-like polymer might improve the seals and throughput obtained by the 
IonWorks HT system. These coatings would improve seals by promoting cell adhesion, 
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and also by “smoothing” sub-micron irregularities in the microfabricated surface of the 
patch plate. Additionally, coating the surface with antibodies to the cell type of interest 
(e.g. CD4+ T cells) might improve seal resistances. 
 
 
Figure 5.2 | Analysis of throughput of CD4+ and CD8+ T cells using IonWorks HT 
technology. For 31 experiments with MS and control patients, each of the 11904 wells of the 
“patch plate” was assessed an outcome of whether the well resulted in a successful Kv1.3 
measurement (stable cells) or an unsuccessful measurement. The reasons for unsuccessful 
measurements were the following: (i) no initial sealing of a cell to the micropore in the well (no 
seal); (ii) establishment of a seal resistance below 75 MΩ (low seal); or (iii) variation of pre- to 
post-compound seal resistances greater than 25%. Columns depict averages and standard 
deviation of the 31 experiments, with CD4+ (yellow) and CD8+ T cells (black) each comprising 
half of the patch plate. P values were computed using Welch’s t test and represent differences 
between CD4+ and CD8+ T cells for the indicated metric.   
  
 The second strategy to improve throughput would be to produce patch plates with 
smaller diameters of micropores. We found that the throughput of the IonWorks HT 
system for lymphocytes depended strongly on the batch of “patch plates” used for 
measurements, as micropore diameters and geometries varied between batches. 
Generally, patch plates with small micropores (<1.8 μm diameter) yielded the highest 
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percentage of successful measurements. In addition, we found that within each patch 
plate, the smallest micropores produced the highest percentage of successful 
measurements of Kv1.3 activity (Fig. 5.3). The IonWorks HT system was designed 
primarily for large cell lines (>20 μm diameter), and these cells are relatively insensitive 
to the size of micropores (19). Lymphocytes (~7 μm), however, are much closer to the 
size of the micropores, which can lead to low seal resistances and instability of T cells on 
the micropores. Two obstacles for reducing micropore size are technological difficulties 
associated with forming repeatable and consistent pores with small diameters (20), and 




Figure 5.3 | Comparison of throughput of CD4+ T cells in specific wells of the patch plate 
with micropores having “small” diameters to the throughput of the entire patch plate. Wells 
with “small diameter” micropores were defined as having an open hole resistance greater than 3.4 
MΩ. Measurements of throughput were from three independent experiments (comprising 574 




 The final strategy for improving throughput would include the development of 
new devices offering a “patch plate” with more than 384 independent wells. Currently, 
MDS Technologies produces the IonWorks Quattro, which is similar to the IonWorks HT 
system except that each well of the “patch plate” contains 64 micropores instead of one 
single micropore (21). Each well, therefore, provides an average of the whole-cell 
currents through less than 64 cells attached to each micropore. Such a system is not 
amenable to measurements with lymphocytes, as fewer than 40% of lymphocytes 
establish seals with micropores. However, the technology of machining 64 micropores in 
each of the 384 wells would be of great applicability if each of the wells were able to be 
individually addressed by electrodes and the fluidics system.   
 In addition to increasing throughput, it would also be useful to be able to monitor 
cellular capacitances of T cells using the IonWorks HT device. Capacitance values, 
which are readily measured in manual patch clamp experiments, are proportional to 
membrane surface area (22), thus allowing computation of Kv1.3 current densities in the 
membranes of attached cells. Measurements of current density would answer the question 
of whether the T cells in patients with MS and RA had high Kv1.3 activity simply 
because they had enlarged T cells or because of increased surface-density of Kv1.3 ion 
channels. The IonWorks HT device currently does not measure capacitances, although 
perhaps the creative design of voltage protocols (involving triangle voltage pulses) may 
afford these measurements. 
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5.5. Profiling of drug compounds that block Kv1.3 ion channels using 
activated human T cells 
 Suppressing Kv1.3 ion channel activity in T cells is a promising approach for 
treating human autoimmune diseases mediated by Tem cells (23). As such, several 
research groups and pharmaceutical companies are actively working to develop human-
suitable drug compounds to block Kv1.3 ion channels (24-26). To test the efficacy of 
such compounds, researchers typically quantify the percentage inhibition of Kv1.3 ion 
channels recombinantly over-expressed in cell lines (27). These cells, while expressing 
high levels of Kv1.3 activity, provide different membrane composition of lipids and 
proteins than human T cells in blood (28). Ideally, promising drug compounds for 
blocking Kv1.3 activity could be screened on human T cells from various subjects 
(including those with disease), in addition to cell lines, to confirm the efficacy of the 
drug. 
 We tested the capability of the high-throughput assay presented in this thesis to 
profile the effects of drug compounds on Kv1.3 activity in human T cells. The IonWorks 
HT system provides several useful features for compound profiling of drugs that block 
ion channels, most notably the ability to add different concentrations to different wells 
across the patch plate. Using cell lines, the IonWorks HT technology allows 
characterization of an entire dose-response curve of a particular drug compound 
(generating an IC50) in a single run (29).  
 T cells, however, provide several complications in using the IonWorks HT 
technology for compound profiling. First, we typically achieved successful Kv1.3 
measurements in ~40% of the wells of the patch plate using T cells (30). This lower 
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throughput (compared to cell lines which have a success rate of >75%) reduces the 
number of measurements of inhibition by a given concentration of drug per experiment. 
Second, T cells isolated directly from blood have low Kv1.3 activity (~0.18 nA average), 
barely above the average leak current caused by the low seal resistance of the IonWorks 
HT system. This low Kv1.3 activity makes it difficult to quantify the percentage of 
inhibition by drug compounds, because the “baseline” current cannot be separated from 
the leak current.   
 To solve the problem of leak current, we used activated human T cells to profile 
drug compounds that block Kv1.3 ion channels. We stimulated freshly isolated human T 
cells for 64 h using 150 ng mL-1 anti-CD3 and anti-CD28 antibodies. After stimulation, 
we isolated CD8+ T cells using magnetic bead separation techniques, and then used these 
isolated cells for IonWorks HT experiments. We previously found that activated T cells 
expressed high levels of Kv1.3 activity, with >75% of cells having Kv1.3 activity greater 
than 0.5 nA before addition of compound (31); we used this threshold of 0.5 nA to 
discard measurements of percentage drug-inhibition that may be affected by leak 
currents. Another advantage of using activated T cells is that these cells afford a higher 
percentage of successful measurements than T cells freshly isolated from human blood 
(30). 
 Using these activated CD8+ T cells, we obtained dose-response curves of the 
inhibition of Kv1.3 ion channels by the drugs margatoxin (IC50 = 110 pM), psora-4 (IC50 
= 3 nM), nifedipine (IC50 = 5 μM), and TRAM-34 (IC50 = 3 μM) (Fig. 5.4). For each 
drug, we performed at least three separate IonWorks HT experiments, with two of the 
experiments being from the same subject and with the second experiment performed 
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immediately following the first (i.e. “back-to-back”) (Table 5.1). To quantify IC50 values, 
we normalized values of percentage inhibition, using the percentage of current block by 
72 nM ShK as the “maximal” value and the percentage of current block by D-PBS as the 
“minimal” value.  
 
Figure 5.4 | Compound-profiling of drug compounds that block Kv1.3 ion channels using 
activated human CD8+ T cells. (A) Effects of margatoxin on inhibition of Kv1.3 activity. 
Results are combined from two consecutive experiments from the same human subject. The red 
line indicates a logistic fit to the dose-dependent inhibition of Kv1.3 activity by margatoxin. (B) 
Same as panel (A), but profiling the effects of nifedipine instead of margatoxin. (C) Same as 
panel (A), except profiling the effects of psora-4. (D) Same as panel (A) except profiling the 
effects of TRAM-34. Note, TRAM-34 was insoluble above 15 μM. Percentage inhibition was 
normalized for each drug compound, using 72 nM ShK to determine “maximal inhibition” and 
using D-PBS to determine “minimal inhibition”. 
  
 Using each of the four drugs, we were able to produce representative dose-
response curves depicting the percentage current block as a function of concentration of 
drug compound (Fig. 5.4). The curve for TRAM-34 did not exhibit a plateau at maximal 
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inhibition of Kv1.3 activity because of drug insolubility above 15 μM. When combining 
“back-to-back” experiments, we obtained IC50 values for margatoxin, nifedipine, and 
TRAM-34 that were within 10% of the listed value for inhibition of Kv1.3 currents 
(Table 5.1). In contrast, values from single experiments varied in IC50 values, even 
between consecutive experiments with the same subject (Table 5.1). These results 
suggest that single experiments using the IonWorks HT technology using T cells are not 
sufficient to obtain IC50 values drug compounds that block Kv1.3 activity, presumably 
due to the low numbers of successful measurements of percentage block for a given 
concentration of drug. 
 Interestingly, experiments with psora-4 using T cells on the IonWorks HT 
instrument produced IC50 values that were 5- to 7-fold higher than reported in literature 
(Table 5.1). These elevated IC50 values were observed using two separate human subjects 
and combining consecutive experiments (Table 5.1). A primary reason for these elevated 
IC50 values may be interactions between psora-4 and exposed surfaces in the fluidics and 
patch-plate wells of the IonWorks HT instrument. Non-specific binding to these surfaces 
would result in an elevated IC50 value, and such effects have been reported for other 
compounds using automated high-throughput electrophysiology (29). 
 This work, therefore, demonstrates that automated high-throughput 
electrophysiology technology can provide a platform for obtaining IC50 values for drug 
compounds that block Kv1.3 ion channels using human lymphocytes. While two 
consecutive experiments were needed to obtain representative IC50 values on activated 
human T cells, several factors may improve the accuracy of the assay using single 
experiments. First, we recently found that stimulating T cells with IL-2 in addition to 
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anti-CD3 antibodies provided 1.5- to 2-fold higher average Kv1.3 current than in T cells 
stimulated with anti-CD28 and anti-CD3 antibodies. Such elevated Kv1.3 currents would 
enable higher throughput (more cells with pre-compound current greater than 0.5 nA) and 
improved accuracy of percentage inhibition especially at concentrations near the IC50 
value. A second enhancement might include modifications to the “patch plate” surface 
(discussed above) to improve seal resistances and throughput of T cells on the IonWorks 
device. Even without enhancements, the methodology presented here provides an 
enabling tool that affords rapid compound profiling of drug compounds that block Kv1.3 
activity using primary human T cells, which are ultimately the target of the these 
compounds (24). 
 
5.6. Simultaneous measurement of Kv1.3 and KCa3.1 channels using high-
throughput electrophysiology 
 The assay presented in this thesis measures, specifically, Kv1.3 activity in human 
T cells. An ideal assay for quantifying K+ ion channel activity in T cells, however, would 
also measure activity of the other major K+ ion channel in T cells, KCa3.1. Wulff et al. 
showed that T cells selectively upregulate either Kv1.3 or KCa3.1 ion channels after 
stimulation, depending on phenotype (15). These findings, however, were obtained using 
manual patch clamp using a limited number of cells (15). Since both channels regulate 
Ca2+-signaling upon activation, a high-throughput approach to profile Kv1.3 and KCa3.1 
activity in the same cell might reveal interesting and unknown K+ channel distributions, 
especially in the context of human disease. In addition, profiling both channels at the 
same time would allow rapid characterization of ion channel distribution in a range of 
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immune cell types, such as regulatory T cells, Th-1, Th-2, or Th-17 cells (all CD4+), in 
which K+ channel distributions have not yet been reported. 
Table 5.1. Summary of compound profiling of drugs that block Kv1.3 ion channels 
using activated human T cells 
Experiment Measured IC50 Hill slope (p) 
Pearson’s correlation 
coefficient (r) 
Margatoxin (IC50 = 110 pM) 
Control #1, Exp. #1 59.6 ± 257 pM 15.5 0.92 
Control #1, Exp. #2 322 ± 121 pM 0.65 ± 0.14 0.92 
Control #1, Avg 110 ± 30 pM 0.94 ± 0.21 0.95 
Control #2 264 ± 68 pM 2.9 ± 1.5 0.90 
Nifedipine (IC50 = 5 μM) 
Control #3, Exp. #1 4.9 ± 2.9 μM 0.7 ± 0.3 0.83 
Control #3, Exp. #2 4.4 ± 1.2 μM 1.4 ± 0.5 0.94 
Control #3, Avg 4.7 ± 1.6 μM 1.2 ± 0.4 0.92 
Control #4 3.6 ± 1.1 μM 2.2 ± 1.4 0.86 
TRAM-34 (IC50 = 3 μM) * 
Control #5, Exp #1 1.8 ± 0.5 μM 2.2 ± 1.5 0.84 
Psora-4 (IC50 = 3 nM) 
Control #6, Exp #1 22.6 ± 6.8 nM 2.1 ± 1.2 0.92 
Control #6, Exp #2 20.5 ± 7.4 nM 0.7 ± 0.2 0.92 
Control #6, Avg 22.7 ± 5.2 nM 1.2 ± 0.3 0.96 
Control #7, Exp #1 19.8 ± 12.6 nM 0.7 ± 0.3 0.80 
Control #7, Exp #2 14.1 ± 12.3 nM 1.2 ± 1.1 0.50 




 There are two major problems with measuring KCa3.1 channels in T cells using 
the IonWorks HT technology. First, T cells freshly isolated from blood express low 
numbers of KCa3.1 channels (10-20 channels per cell) (32). These low numbers, coupled 
with a single channel conductance of ~12 pS (33), may make it impossible to distinguish 
KCa3.1 from the leak current in freshly isolated T cells (due to the low seal resistance of 
T cells on the IonWorks HT device). Activated T cells, however, express 20-fold more 
KCa3.1 channels than resting T cells (15), making possible the measurement of KCa3.1 
channels above the background leak current.  
 A second problem is that the IonWorks HT system does not permit perfusion of 
the intracellular recording solution. Since KCa3.1 channels open in response to increases 
in intracellular Ca2+ levels (which is typically accomplished by perfusion of a Ca2+high 
intracellular solution using traditional patch clamp (34)), this increase in Ca2+ must come 
from the extracellular solution in the IonWorks HT system. One strategy is to deliver 
compounds that open plasma membrane CRAC channels in the T cell attached to the 
micropore in each well to increase [Ca2+]i from the extracellular solution (Fig. 5.5). Either 
thapsigargin (which opens intracellular stores of Ca2+ to activate plasma membrane 
CRAC channels) or ionomycin (a Ca2+ ionophore) might be able to elevate the 
intracellular concentration of Ca2+ to activate KCa3.1 channels (35).  
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Figure 5.5  |  Strategy for measuring Kv1.3 and KCa3.1 channels simultaneously in T cells 
using IonWorks HT technology. (A) Voltage-protocol for measuring Kv1.3 and KCa3.1 ion 
channels in the same experiment. A ramp protocol affords elucidation of ligand-gated KCa3.1 
channels at hyperpolarizations and small depolarizations, while voltage-gated channels open 
sharply upon depolarization above an activating threshold. (B) General strategy used in this 
experiment. First, whole-cell electrical current was recorded using the voltage-ramp in (A), with 
only Kv1.3 channels opening upon depolarization. Then, 1 μM ionomycin was added (5 min 
incubation time) to the attached T cells to increase [Ca2+]i and open KCa3.1 channels. Whole-cell 
current was recorded a second time, with both KCa3.1 and Kv1.3 channels contributing to the 
recorded current. (C) Sample measurement with a cell that exhibited a stable seal resistance upon 
compound addition, with pre-compound current represented in black and post-compound current 
in red. The dashed lines depict a strategy to quantify, respectively, KCa3.1 and Kv1.3 channel 
contributions to the overall current. (D) A second sample measurement of Kv1.3 and KCa3.1 
currents in the same cell.       
 
 We performed a proof-of-principle experiment to measure Kv1.3 and KCa3.1 
channels in parallel in mitogen activated CD4+ T cells using the IonWorks HT device. In 
this experiment, we first measured whole-cell electrical current using a voltage ramp, 
with Kv1.3 ion channels opening upon depolarization, and then added ionomycin (1 μM), 
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using the automated fluidics of the IonWorks HT device to each well of patch plate (Fig. 
5.5). After incubation, we re-measured the whole cell electrical current, which was now 
composed of both Kv1.3 and KCa3.1 activity. While this experiment did seem to permit 
elucidation of both Kv1.3 and KCa3.1 channels in the same cells (Fig. 5.5), the apparent 
KCa3.1 activity (Fig. 5.5) may be due to increases of the leak current after addition of 
ionomycin. Optimization of protocols (e.g. concentration and incubation times of 
thapsigargin or ionomycin) using manual patch-clamp or automated single-cell planar 
patch-clamp technologies (Nanion, Munich, Germany (36)) will be an important next 
step before trying again to measure KCa3.1 channels using the IonWorks HT device. 
 
5.7. Determining the molecular mechanisms of increased Kv1.3 activity 
after stimulation of T cells 
 In Chapter 3, we profiled the effects of immunosuppressive drugs on regulating 
Kv1.3 activity upon stimulation of T cells. Several questions, however, remain about the 
mechanisms by which Kv1.3 activity increases after stimulation: (i) is the increase the 
result of increased translation of new Kv1.3 proteins?; (ii) is the increase the result of 
insertion of vesicles containing Kv1.3 proteins into the plasma membrane?; and (iii) 
which additional pathways might be involved in affecting Kv1.3 regulation?  
 An approach to determine whether increased Kv1.3 activity correlates to increase 
Kv1.3 protein levels involves using Western blot techniques to analyze Kv1.3 protein 
levels in CD4+ T cells isolated after stimulation. Useful experiments would involve 
analysis of Kv1.3 protein levels in CD4+ T pre-treated with immunosuppressive drugs 
using different stimulation conditions, as well as time-course studies of the changes in 
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protein levels following stimulation. Three difficulties associated with these studies are: 
(i) difficulties associated with quantifying protein levels in Western blot studies; (ii) 
selection of a reference protein with levels that do not change upon stimulation (e.g. 
GAPDH may not be sufficient); and (iii) selection of a polyclonal antibody to Kv1.3 
proteins, as commercial sources may not be specific to Kv1.3 ion channels (personal 
communication with Prof. Christine Beeton).  
 In addition to Western blot studies, there are several additional 
immunosuppressive drugs that may provide useful insights into the regulation of Kv1.3 
activity. It would especially be interesting to examine a more selective and potent 
inhibitor of Jak-3 than tyrphostin AG-490 (for example the recently-developed CP-
690550 compound, Pfizer (37)) to verify the specific effects of Jak-3 inhibitors on Kv1.3 
activity. In addition, inhibitors of PI(3)K (LY294002 (Sigma-Aldrich) or wortmannin 
(Sigma-Aldrich)), MAP kinase (U0126 (Sigma-Aldrich)), and AKT (Triciribine, EMD 
Biosciences) might provide insight on the pathways that regulate Kv1.3 activity. One 
problem associated with studying these drugs may be that their effects on IL-2 and IL-2R 
expression make it difficult to isolate effects on Kv1.3 activity. In addition, LY294002 
has been reported to block Kv ion channels (38). 
 
5.8. siRNA studies to assess the role of increased Kv1.3 activity in 
activated human T cells 
 To further study the immunological relevance of Kv1.3 regulation in T cells, it 
would be interesting to use small interfering RNA strands (siRNA) to inhibit translation 
of Kv1.3 ion channels in T cells. Such an approach would answer four central questions 
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related to the regulation of ion channels in T cells: (i) whether Kv1.3 activity regulated at 
the transcriptional level; (ii) whether inhibiting the upregulation of Kv1.3 activity affects 
Ca2+-signaling, cytokine secretion, and proliferation of T cells; (iii) whether some cell 
phenotypes (e.g. Tem) are affected by disrupting Kv1.3 regulation more than other 
subsets; and (iv) whether inhibiting the increase in Kv1.3 activity after stimulation can 
provide therapeutic benefit in animal models of autoimmune disease.  
 While siRNA technology offers a specific tool to disrupt regulation of Kv1.3 
activity, there are significant challenges associated with delivering siRNA to primary 
lymphocytes. Typically, lymphocytes are resistant to transfection by conventional 
reagents including cationic lipids and polymers (39). Electroporation experiments 
succeed in delivering siRNA to lymphocytes in vitro, although this technique may lead to 
significant cell death (40). Promising new methods for delivering siRNA to lymphocytes 
include viral vectors (41) and antibody fragment-protamine fusion proteins (mixed with 
siRNA) to target siRNA to particular T cells (42). 
 
5.9. Modeling the roles of Kv1.3 and KCa3.1 ion channels in regulating T 
cell activation 
 In addition to using high-throughput screening to measure Kv1.3 ion channels in 
T cells, we also used inhibitors of Kv1.3 and KCa3.1 ion channels to explore the roles of 
these ion channels in T cells (Fig. 5.6). Five interesting findings arose from these studies. 
(i) Blocking KCa3.1 ion channels (with TRAM-34) alone had no effect on expression of 
activation markers (CD25, CD26) or proliferation of CD4+ T cells after stimulation (Fig. 
5.6A,B). (ii) Blocking KCa3.1, in combination with blocking Kv1.3, had profound effects 
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on reducing proliferation and expression of activation markers in T cells activated by 
anti-CD3 antibodies (Fig. 5.6A,C). The effects of the inhibition of both Kv1.3 and  
KCa3.1 were significantly greater than blocking either channel alone. (iii) When 
stimulation protocols employed either anti-CD28 antibodies or recombinant IL-2 (in 
addition to anti-CD3 antibodies), K+ channel blockers had no effects on either CD25 
expression or T cell proliferation. (Fig. 5.6A,C). (iv) Expression of CD26 in CD4+ T cells 
after activation was especially sensitive to drug compounds that block Kv1.3 channels.  
These compounds significantly CD26 expression even when anti-CD28 antibodies were 
added to stimulation (Fig. 5.6B). And (v), inhibiting either Kv1.3 or KCa3.1 ion channels 
reduced Ca2+ influx in freshly isolated T cells after stimulation. The combination of 
blocking both channels, however, produced the largest reduction in Ca2+ influx (Fig. 
5.6D). It is interesting that blocking KCa3.1 ion channels had a similar effect in reducing 
influx of Ca2+ compared to blocking Kv1.3 channels; inhibiting KCa3.1 channels, 
however, had no measurable effects on downstream events such as proliferation and 
expression of activation markers (Fig. 5.6, green columns). 
 One approach that may elucidate the roles of Kv1.3 and KCa3.1 ion channels in 
regulating Ca2+-signaling in T cells would be to use confocal microscopy to monitor Ca2+ 
signaling in single T cells. While a microscopic-based approach has been used since the 
1980’s to measure [Ca2+]i in individual T cells (43), the effects of selective blockers of 
Kv1.3 and KCa3.1 ion channels on single-cell Ca2+-signaling have not been elucidated 
using human T cells (34). These experiments would provide insights into the roles of 
KCa3.1 and Kv1.3 ion channels in generating different types of Ca2+-signals (e.g. 
oscillations) (44, 45). In addition, these experiments would allow examination of single-
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cell Ca2+-signaling in different phenotypes of T cells (e.g. Tem cells) to probe the effects 
of K+-channels in regulating Ca2+-signaling in different phenotypes of cells. 
 
 
Figure 5.6 | Flow cytometric analysis of the effects of K+-channel blockers on expression of 
activation markers, proliferation, and Ca2+-signaling in CD4+ T cells. (A) Expression of 
CD25 in gated CD4+ T cells selected from PBMCs cultured with either anti-CD3 antibodies (four 
columns on left) or anti-CD28 plus anti-CD3 antibodies (right) for ~64 h. PBMCs were pre-
incubated with either 100 nM ShK to block Kv1.3 channels, 1000 nM TRAM-34 to block 
KCa3.1 channels, 100 nM ShK plus 1000 nM TRAM-34, or with no added ion channel blockers. 
Expression levels are expressed as the average and standard deviation of relative mean 
fluorescence intensity (MFI) from four human subjects. Expression was normalized for each 
subject using the MFI of cells cultured with anti-CD3 antibodies as the “maximum” value, and 
MFI of cells cultured without any mitogenic antibodies as the “minimum” value. (B) Expression 
of CD26 in gated CD4+ T cells selected from PBMCs described in (A). (C) Proliferation of CD4+ 
T cells selected from PBMCs initially loaded with 0.25 μM CFSE dye and cultured as described 
in (A) for 96 h. Asterisks (**) represent statistical significance (p<0.01 using Welch’s t test) 
compared to the condition of no added ion channel blockers. (D) Calcium signaling, measured 
using flow cytometry to measure the ratio of two Ca2+ sensitive dyes, in CD4+ T cells from 
freshly drawn blood (left) or after stimulation of PBMCs for 64 h with anti-CD3 plus anti-CD28 
antibodies (right). PBMCs were pre-incubated with the indicated K+-channel blocker for 30 min 
prior to flow cytometric analysis. Thapsigargin (Tg, 1 μM) was added to cells after 30 seconds of 
analysis to initiate Ca2+-signaling. The bar graphs (bottom panel) represent the average 
intracellular Ca2+ levels at the 350 s time-point (represented by the dashed line). Ca2+-
measurements are representative of experiments with two different human subjects. 
 
 156
 In addition to quantifying the effects of K+-channel blockers on Ca2+-signaling in 
single cells, it would also be useful to construct mathematical and computer models of 
Ca2+-signaling in T cells. There are several factors leading to increases of [Ca2+]i, with 
the main sources being the release of Ca2+ from intracellular stores as well as the opening 
of plasma membrane Ca2+-channels to allow influx of Ca2+ from outside the cell (46). 
There are also several “sinks” leading to decreased [Ca2+]i, including: (i) sarco-
endoplasmic reticulum Ca2+-ATPases (SERCA) pumps that pump Ca2+ from the cytosol 
back into the ER; (ii) plasma membrane Ca2+-ATPases (PMCA) that pump Ca2+ from the 
cytosol out of the cell; and (iii) mitochondrial Ca2+ pumps (46). Mathematical models 
that combined all of these sources and sinks, and incorporated membrane potential and 
K+ channel distributions, would allow precise studies of the effects of K+ channels on 
regulating Ca2+-signaling.   
 While most recent literature has focused on the role of K+-channels in Ca2+-
signaling, one of the earliest proposed roles K+-channels was to regulate cellular volume 
(47, 48). With the finding that Kv1.3 ion channel activity is regulated pathways 
traditionally associated with T cell growth and proliferation (Chapters 2, 3), it would be 
interesting to revisit the roles of Kv1.3 ion channels in regulating volume. For example, it 
would be interesting to measure regulatory volume decrease (RVD) in different 
phenotypes of T cells both before and after stimulation. Such studies would also explore 
the effects of blockers of Kv1.3 activity on RVD in different T cell phenotypes, which 
has not been determined. For example, a potential role of the greatly increased Kv1.3 
activity in activated Tem cells might be to enhance the ability of these T cells to regulate 
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volume. Such increased RVD might aid these cells in rapidly homing to peripheral tissues 
to fight infection, thus linking Kv1.3 activity to cellular migration.  
 
5.10. Concluding remarks 
 Ion channels are fascinating proteins that are strongly implicated in the 
pathogenesis of several human diseases (23). The work presented in this thesis provides a 
novel methodology that enables new experimental possibilities to study these ion 
channels in cells of the immune system. We explored several of these possibilities, 
including immunological studies of the pathways that regulate Kv1.3 activity in human T 
cells, and clinical studies profiling the distributions of Kv1.3 activity in patients with 
autoimmune disease. The resulting insights from this work suggest that Kv1.3 activity is 
a useful and sensitive marker of active T cell mediated inflammation in human diseases 
such as MS and RA. While future experiments must be performed to establish high-
throughput measurements of ion channel activity as an effective clinical test, the methods 
presented in this thesis may have significant impact as a quantitative tool to diagnose and 
monitor human autoimmune diseases. 
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